Author: "Daria Fomina" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Daria Fomina"' showing total 57 results

Start Over Author "Daria Fomina"

57 results on '"Daria Fomina"'

1. Disease burden, clinical management and unmet treatment need of patients with moderate to severe atopic dermatitis; consensus statements, insights and practices from CERTADE (Central/Eastern EU, Russia, Turkiye AD Experts) Delphi panel

Author: Magdalena Trzeciak, Lidia Rudnicka, Petr Arenberger, Burhan Engin, Andrey L'vov, Sibel Alper, Erkan Alpsoy, Nina Benáková, Svetlana Bobko, Murat Borlu, Magdalena Czarnecka-Operacz, Olga Elisyutina, Tulin Ergun, Ilgen Ertam, Elena Fedenko, Olga Filipovská, Daria Fomina, Aida Gadzhigoroeva, Martina Kojanová, Aleksandra Lesiak, Anna Michenko, Nikolay Murashkin, Witold Owczarek, Esen Özkaya, Zuzana Plzáková, Adam Reich, Marie Selerova, and Burcu A. Gurbuz
Subjects: atopic dermatitis, disease burden, management, treatment, moderate-to-severe AD, Medicine (General), R5-920
Abstract: BackgroundThere is limited insight into the current disease burden and everyday clinical management of moderate-to- severe AD in Poland, Czechia, Russia, and Turkiye. Therefore, this study aimed to get information-driven insights regarding the current disease burden and clinical management of patients with moderate-to-severe AD with common and differentiating aspects of the patient journey and establish a consensus.MethodsIn this modified 2-round Delphi panel, 133 questions were asked in total to 27 dermatologists. A consensus was achieved when 70% of the panel members strongly agreed or agreed (or strongly disagreed or disagreed) with an item. Statements with
Published: 2024
Full Text: View/download PDF

2. A concept for integrated care pathways for atopic dermatitis—A GA2LEN ADCARE initiative

Author: Torsten Zuberbier, Amir Abdul Latiff, Xenofon Aggelidis, Matthias Augustin, Radu‐Gheorghe Balan, Christine Bangert, Lisa Beck, Thomas Bieber, Jonathan A. Bernstein, Marta Bertolin Colilla, Alejandro Berardi, Anna Bedbrook, Carsten Bindslev‐Jensen, Jean Bousquet, Marjolein deBruin‐Weller, Dayanne Bruscky, Betul Buyuktiryaki, Giorgio Walter Canonica, Carla Castro, Natia Chanturidze, Herberto Jose Chong‐Neto, Chia‐Yu Chu, Leena Chularojanamontri, Michael Cork, Roberta F. J. Criado, Laia Curto Barredo, Adnan Custovic, Ulf Darsow, Arben Emurlai, Ana dePablo, Stefano DelGiacco, Giampiero Girolomoni, Tanja Deleva Jovanova, Mette Deleuran, Nikolaos Douladiris, Bruno Duarte, Ruta Dubakiene, Esben Eller, Batya Engel‐Yeger, Luis Felipe Ensina, Nelson Rosario Filho, Carsten Flohr, Daria Fomina, Wojciech Francuzik, Maria Laura Galimberti, Ana M. Giménez‐Arnau, Kiran Godse, Charlotte Gotthard Mortz, Maia Gotua, Michihiro Hide, Wolfram Hoetzenecker, Nicolas Hunzelmann, Alan Irvine, Carolyn Jack, Ioanna Kanavarou, Norito Katoh, Tamar Kinaciyan, Emek Kocatürk, Kanokvalai Kulthanan, Hilde Lapeere, Susanne Lau, Mariana Machado Forti Nastri, Michael Makris, Eli Mansour, Alexander Marsland, Mara Morelo Rocha Felix, Ana Paula Moschione Castro, Eustachio Nettis, J. F. Nicolas, Audrey Nosbaum, Mikaela Odemyr, Niki Papapostolou, Claudio A. S. Parisi, Sushil Paudel, Jonny Peter, Prakash Pokharel, Luis Puig, Tamara Quint, German Dario Ramon, Frederico Regateiro, Giampaolo Ricci, Cristine Rosario, Cansin Sackesen, Peter Schmid‐Grendelmeier, Esther Serra‐Baldrich, Kristina Siemens, Cathrine Smith, Petra Staubach, Katarina Stevanovic, Özlem Su‐Kücük, Gordon Sussman, Simona Tavecchio, Natasa Teovska Mitrevska, Diamant Thaci, Elias Toubi, Claudia Traidl‐Hoffmann, Regina Treudler, Zahava Vadasz, Ingrid vanHofman, Maria Teresa Ventura, Zhao Wang, Thomas Werfel, Andreas Wollenberg, Ariana Yang, Yik Weng Yew, Zuotao Zhao, Ricardo Zwiener, and Margitta Worm
Subjects: atopic dermatitis, eczema, guidance, ICP, integrated care pathways, multidisciplinary, Immunologic diseases. Allergy, RC581-607
Abstract: Abstract Introduction The integrated care pathways for atopic dermatitis (AD‐ICPs) aim to bridge the gap between existing AD treatment evidence‐based guidelines and expert opinion based on daily practice by offering a structured multidisciplinary plan for patient management of AD. ICPs have the potential to enhance guideline recommendations by combining interventions and aspects from different guidelines, integrating quality assurance, and describing co‐ordination of care. Most importantly, patients can enter the ICPs at any level depending on AD severity, resources available in their country, and economic factors such as differences in insurance reimbursement systems. Methods The GA2LEN ADCARE network and partners as well as all stakeholders, abbreviated as the AD‐ICPs working group, were involved in the discussion and preparation of the AD ICPs during a series of subgroup workshops and meetings in years 2020 and 2021, after which the document was circulated within all GAL2EN ADCARE centres. Results The AD‐ICPs outline the diagnostic procedures, possible co‐morbidities, different available treatment options including differential approaches for the pediatric population, and the role of the pharmacists and other stakeholders, as well as remaining unmet needs in the management of AD. Conclusion The AD‐ICPs provide a multidisciplinary plan for improved diagnosis, treatment, and patient feedback in AD management, as well as addressing critical unmet needs, including improved access to care, training specialists, implementation of educational programs, assessment on the impact of climate change, and fostering a personalised treatment approach. By focusing on these key areas, the initiative aims to pave the way for a brighter future in the management of AD.
Published: 2023
Full Text: View/download PDF

3. Temporal Clinical and Laboratory Response to Interleukin-6 Receptor Blockade With Tocilizumab in 89 Hospitalized Patients With COVID-19 Pneumonia

Author: Daria Fomina, Mar’yana A. Lysenko, Irina P. Beloglazova, Zinaida Yu. Mutovina, Nataliya G. Poteshkina, Inna V. Samsonova, Tat’yana S. Kruglova, Anton A. Chernov, and Alexander V. Karaulov
Subjects: covid-19, sars-cov-2, pneumonia, cytokine storm, il-6, tocilizumab, Pathology, RB1-214, Immunologic diseases. Allergy, RC581-607
Abstract: Background: Pandemic COVID-19 pneumonia due to SARS-2 is an important cause of morbidity and mortality. Emerging evidence links poor outcomes to an inflammatory cytokine storm. Methods: We treated 89 hospitalized patients with COVID-19 pneumonia and heightened systemic inflammation (elevated serum C reactive protein and interleukin-6 levels) with an infusion of tocilizumab (TCZ), a human monoclonal IgG1 antibody to the interleukin-6 receptor. Results: Clinical and laboratory evidence of improvement was evident when baseline and 1-2-day post-infusion indices were compared. Among the 72 patients receiving supplemental oxygen without mechanical ventilation, severity of condition on the NEWS2 scale scores fell from 5 to 2 (P30 mg/L) and low lymphocyte counts (
Published: 2020
Full Text: View/download PDF

4. Chronic urticaria patients are interested in apps to monitor their disease activity and control: A UCARE CURICT analysis

Author: Ivan Cherrez‐Ojeda, Emanuel Vanegas, Annia Cherrez, Miguel Felix, Karsten Weller, Markus Magerl, Rasmus Robin Maurer, Valeria L. Mata, Alicja Kasperska‐Zajac, Agnieszka Sikora, Daria Fomina, Elena Kovalkova, Kiran Godse, Nimmagadda Dheeraj Rao, Maryam Khoshkhui, Sahar Rastgoo, Roberta F. J. Criado, Mohamed Abuzakouk, Deepa Grandon, Martijn B. A. Van Doorn, Solange Oliveira Rodrigues Valle, Eduardo Magalhães De Souza Lima, Simon Francis Thomsen, German D. Ramón, Edgar E. Matos Benavides, Andrea Bauer, Ana M. Giménez‐Arnau, Emek Kocatürk, Carole Guillet, Jose Ignacio Larco, Zuo‐Tao Zhao, Michael Makris, Carla Ritchie, Paraskevi Xepapadaki, Luis Felipe Ensina, Sofia Cherrez, and Marcus Maurer
Subjects: apps, chronische induzierbare urtikaria, chronische spontane urtikaria, chronische urtikaria, UCARE, Immunologic diseases. Allergy, RC581-607
Abstract: Abstract Background Information/communication technologies such as mobile phone applications (apps) would enable chronic urticaria (CU) patients to self‐evaluate their disease activity and control. Yet, recently Antó et al (2021) reported a global paucity of such apps for patients with CU. In this analysis, we assessed patient interest in using apps to monitor CU disease activity and control using questions from the chronic urticaria information and communication technologies (CURICT) study. Methods The methodology for CURICT has been reported. Briefly, a 23‐item questionnaire was completed by 1841 CU patients from 17 UCAREs across 17 countries. Here, we analyzed patient responses to the CURICT questions on the use of apps for urticaria‐related purposes. Results As previously published, the majority of respondents had chronic spontaneous urticaria (CSU; 63%; 18% chronic inducible urticaria (CIndU) [CIndu]; 19% with both), were female (70%) and in urban areas (75%). Over half of patients were very/extremely interested in an app to monitor disease activity (51%) and control (53%), while only ∼1/10 were not. Patients with both urticaria types versus those with CSU only (odds ratio [OR], 1.36 [1.03–1.79]) and females versus males (OR [95% CI], 1.47 [1.17–1.85]) were more likely to be very to extremely interested in an app to assess disease control. Conclusions Overall, half of the patients with CU were very to extremely interested in using an app to assess their disease activity and control. Development of well‐designed apps, specific to disease types (CSU, CIndU, CSU + CIndU, etc), validated by experts across platforms would help improve the management and possibly outcomes of CU treatment while providing important patient information to be used in future research.
Published: 2021
Full Text: View/download PDF

5. How are patients with chronic urticaria interested in using information and communication technologies to guide their healthcare? A UCARE study

Author: Ivan Cherrez-Ojeda, Emanuel Vanegas, Annia Cherrez, Miguel Felix, Karsten Weller, Markus Magerl, Rasmus Robin Maurer, Valeria L. Mata, Alicja Kasperska-Zajac, Agnieszka Sikora, Daria Fomina, Elena Kovalkova, Kiran Godse, Nimmagadda Dheeraj Rao, Maryam Khoshkhui, Sahar Rastgoo, Roberta FJ. Criado, Mohamed Abuzakouk, Deepa Grandon, Martijn B.A. Van Doorn, Solange Oliveira Rodrigues Valle, Eduardo Magalhães De Souza Lima, Simon Francis Thomsen, German D. Ramón, Edgar E. Matos Benavides, Andrea Bauer, Ana M. Giménez-Arnau, Emek Kocatürk, Carole Guillet, Jose Ignacio Larco, Zuo-Tao Zhao, Michael Makris, Carla Ritchie, Paraskevi Xepapadaki, Luis Felipe Ensina, Sofia Cherrez, and Marcus Maurer
Subjects: Chronic urticaria, Information and communication technologies, Internet, e-mail, WhatsApp, Immunologic diseases. Allergy, RC581-607
Abstract: Background: Patients with chronic urticaria (CU) are increasingly using information and communication technologies (ICTs) to manage their health. What CU patients expect from ICTs and which ICTs they prefer remains unknown. We assessed why CU patients use ICTs, which ones they prefer, and what drives their expectations and choices. Methods: In this cross-sectional study, 1841 patients across 17 countries were recruited at UCAREs (Urticaria Centers of Reference and Excellence). Patients with CU who were >12 years old completed a 23-item questionnaire. Results: Most patients were interested in receiving disease information (87.3%), asking physicians about CU (84.1%), and communicating with other patients through ICTs (65.6%). For receiving disease information, patients preferred one-to-one and one-to-many ICTs, especially web browsers. One-to-one ICTs were also the ICTs of choice for asking physicians about urticaria and for communicating with other patients, and e-mail and WhatsApp were the preferred ICTs, respectively. Many-to-many ICTs such as Facebook, Instagram, LinkedIn, and Twitter were least preferred for all 3 purposes. Living in rural areas and higher education were linked to higher odds of being interested in receiving disease information, asking physicians, and communicating with patients through ICTs. Conclusions: Most patients and especially patients with higher education who live in rural areas are interested in using ICTs for their healthcare, but prefer different ICTs for different purposes, ie, web browsers for obtaining information, e-mail for asking physicians, and WhatsApp for communicating with other patients. Our findings may help to improve ICTs for CU.
Published: 2021
Full Text: View/download PDF

6. Molecular Allergen-Specific IgE Recognition Profiles and Cumulative Specific IgE Levels Associated with Phenotypes of Cat Allergy

Author: Ksenja Riabova, Antonina V. Karsonova, Marianne van Hage, Ulrika Käck, Jon R. Konradsen, Hans Grönlund, Daria Fomina, Evgeny Beltyukov, Polina A. Glazkova, Dmitry Yu. Semenov, Rudolf Valenta, Alexander Karaulov, and Mirela Curin
Subjects: allergy, allergen molecules, cat allergy, cat allergens, IgE reactivity, allergy diagnosis, Biology (General), QH301-705.5, Chemistry, QD1-999
Abstract: Cat allergy is a major trigger factor for respiratory reactions (asthma and rhinitis) in patients with immunoglobulin E (IgE) sensitization. In this study, we used a comprehensive panel of purified cat allergen molecules (rFel d 1, nFel d 2, rFel d 3, rFel d 4, rFel d 7, and rFel d 8) that were obtained by recombinant expression in Escherichia coli or by purification as natural proteins to study possible associations with different phenotypes of cat allergy (i.e., rhinitis, conjunctivitis, asthma, and dermatitis) by analyzing molecular IgE recognition profiles in a representative cohort of clinically well-characterized adult cat allergic subjects (n = 84). IgE levels specific to each of the allergen molecules and to natural cat allergen extract were quantified by ImmunoCAP measurements. Cumulative IgE levels specific to the cat allergen molecules correlated significantly with IgE levels specific to the cat allergen extract, indicating that the panel of allergen molecules resembled IgE epitopes of the natural allergen source. rFel d 1 represented the major cat allergen, which was recognized by 97.2% of cat allergic patients; however, rFel d 3, rFel d 4, and rFel d 7 each showed IgE reactivity in more than 50% of cat allergic patients, indicating the importance of additional allergens in cat allergy. Patients with cat-related skin symptoms showed a trend toward higher IgE levels and/or frequencies of sensitization to each of the tested allergen molecules compared with patients suffering only from rhinitis or asthma, while there were no such differences between patients with rhinitis and asthma. The IgE levels specific to allergen molecules, the IgE levels specific to cat allergen extract, and the IgE levels specific to rFel d 1 were significantly higher in patients with four different symptoms compared with patients with 1–2 symptoms. This difference was more pronounced for the sum of IgE levels specific to the allergen molecules and to cat extract than for IgE levels specific for rFel d 1 alone. Our study indicates that, in addition to rFel d 1, rFel d 3, rFel d 4, and rFel d 7 must be considered as important cat allergens. Furthermore, the cumulative sum of IgE levels specific to cat allergen molecules seems to be a biomarker for identifying patients with complex phenotypes of cat allergy. These findings are important for the diagnosis of IgE sensitization to cats and for the design of allergen-specific immunotherapies for the treatment and prevention of cat allergy.
Published: 2022
Full Text: View/download PDF

7. The usage, quality and relevance of information and communications technologies in patients with chronic urticaria: A UCARE study

Author: Marcus Maurer, Karsten Weller, Markus Magerl, Rasmus Robin Maurer, Emanuel Vanegas, Miguel Felix, Annia Cherrez, Valeria L. Mata, Alicja Kasperska-Zajac, Agnieszka Sikora, Daria Fomina, Elena Kovalkova, Kiran Godse, Nimmagadda Dheeraj Rao, Maryam Khoshkhui, Sahar Rastgoo, Roberta Fachini Jardim Criado, Mohamed Abuzakouk, Deepa Grandon, Martijn van Doorn, Solange Olliveira Rodrigues Valle, Eduardo Magalhães de Souza Lima, Simon Francis Thomsen, German D. Ramón, Edgar E. Matos Benavides, Andrea Bauer, Ana Maria Giménez-Arnau, Emek Kocatürk, Carole Guillet, Jose Ignacio Larco, Zuo-Tao Zhao, Michael Makris, Carla Ritchie, Paraskevi Xepapadaki, Luis Felipe Ensina, Sofia Cherrez, and Ivan Cherrez-Ojeda
Subjects: (3–5) ICT, Information and communications technology, Urticaria, Self-management, Immunologic diseases. Allergy, RC581-607
Abstract: Background: Chronic urticaria (CU) is characterized by itchy recurrent wheals, angioedema, or both for 6 weeks or longer. CU can greatly impact patients' physical and emotional quality of life. Patients with chronic conditions are increasingly seeking information from information and communications technologies (ICTs) to manage their health. The objective of this study was to assess the frequency of usage and preference of ICTs from the perspective of patients with CU. Methods: In this cross-sectional study, 1800 patients were recruited from primary healthcare centers, university hospitals or specialized clinics that form part of the UCARE (Urticaria Centers of Reference and Excellence) network throughout 16 countries. Patients were >12 years old and had physician-diagnosed chronic spontaneous urticaria (CSU) or chronic inducible urticaria (CIndU). Patients completed a 23-item questionnaire containing questions about ICT usage, including the type, frequency, preference, and quality, answers to which were recorded in a standardized database at each center. For analysis, ICTs were categorized into 3 groups as follows: one-to-one: SMS, WhatsApp, Skype, and email; one-to-many: YouTube, web browsers, and blogs or forums; many-to-many: Instagram, Twitter, Facebook, and LinkedIn. Results: Overall, 99.6% of CU patients had access to ICT platforms and 96.7% had internet access. Daily, 85.4% patients used one-to-one ICT platforms most often, followed by one-to-many ICTs (75.5%) and many-to-many ICTs (59.2%). The daily ICT usage was highest for web browsers (72.7%) and WhatsApp (70.0%). The general usage of ICT platforms increased in patients with higher levels of education. One-to-many was the preferred ICT category for obtaining general health information (78.3%) and for CU-related information (75.4%). A web browser (77.6%) was by far the most commonly used ICT to obtain general health information, followed by YouTube (25.8%) and Facebook (16.3%). Similarly, for CU-specific information, 3 out of 4 patients (74.6%) used a web browser, 20.9% used YouTube, and 13.6% used Facebook. One in 5 (21.6%) patients did not use any form of ICT for obtaining information on CU. The quality of the information obtained from one-to-many ICTs was rated much more often as very interesting and of good quality for general health information (53.5%) and CU-related information (51.5%) as compared to the other categories. Conclusions: Usage of ICTs for health and CU-specific information is extremely high in all countries analyzed, with web browsers being the preferred ICT platform.
Published: 2020
Full Text: View/download PDF

8. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials

Author: Rosana, Agondi, Ahmed, Al Waily, Fabio, Almerigogna, Miguel Angel Tejedor, Alonso, Alfred, Ammoury, Eng Kim, Anne Goh, Robert, Anolik, Ledit, Ardusso, Petr, Arenberger, Nandini, AS, Mohammad, Asefi, Natalia, Astafieva, Anil, Badhwar, Esther Serra, Baldrich, Christine, Bangert, Annick, Barbaud, Zsuzsanna, Bata-Csorgo, Andrea, Bauer, Frederic, Berard, Beata, Bergler-Czop, Gary D, Berman, Jonathan, Bernstein, Subhash Chandra, Bharija, Ramesh M, Bhat, Isabelle, Boccon-Gibod, Ivan, Botev, Knut, Brockow, Philipp, Buck, Paula, Busse, Regis, Campos, Giorgio Walter, Canonica, Irani, Carla, Julia Maria Del, Carmen, Jaime Del, Carpio, Mamatha, Chadalavada, Yoon-Seok, Chang, Amarjit, Cheema, Yi Hsing, Chen, Yuko, Chinuki, Soyun, Cho, Jeong-Hee, Choi, Chia-Yu, Chu, Ronit, Confino, Jonathan, Corren, Roberta, Criado, Claudia De La, Cruz, David M, Cypcar, Pramila, Daftary, Inna, Danilycheva, Kenneth, Dawes, Michelle Joy, De Vera, James, Deangelo, Stefano, Del Giacco, Diana, Deleanu, John, Delgado, Richard, DeMera, Mohamed, Denguezli, Heinrich, Dickel, Le Huu, Doanh, Sinan, Dogan, Marie Sylvie, Doutre, Anne Sophie, Dupond, Anton, Edin, Kent, EDWARD, Swarna, Ekanayake-Bohling, Daniel, Elbirt, David, Elkayam, Anne, Ellis, Shaunagh, Emanuel, Alexander, Emeliyanov, Burhan, Engin, Luis Felipe, Ensina, Ignacio Antepara, Ercoreca, Safiye, Ergun, Jose Luis Lopez, Estebaranz, Rustem, Fassakhov, Daria, Fomina, Linda, Ford, Mariangela, Francomano, Todd, Funkhouser, Remi, Gagnon, Ricardo, Galimberti, Cesar Alberto, Galvan Calle, Clovis, Galvao, Gabriel, Gattolin, Pierre-Dominique, Ghislain, Ana Maria, Gimenez Arnau, Elliot, Ginchansky, Francoise, Giordano-Labadie, Stanislav, Givirovsky, Kiran, Godse, Shaila, Gogate, Alan, Goldsobel, Francisca, Gomez, Rene Maximiliano, Gomez, Erika, Gonzalez, Paula Ribo, Gonzalez, Dimitar, Gospodinov, Clive, Grattan, Martine, Grosber, Gary, Gross, Francisco Jose Gomez, Guimera Martin-Neda, Rolland, Gyulai, Svetlana, Hadvabova, Suzana Ljubojevic, Hadzavdic, Hadi, Hamam, Daniela, Hasicova, Koremasa, Hayama, Pravin, Hissaria, Anna, Hjerppe, Ivan, Hlinka, Moises Labrador, Horrillo, Connie, Hsu, Yu-Huei, Huang, Iftikhar, Hussain, Atsuyuki, Igarashi, Beata, IMKO-WALCZUK, Huseyin Serhat, Inaloz, Rossella, Intravaia, Neal, Jain, Sanjeev, Jain, Thilo, Jakob, Ruth Cerino, Javier, Antonio, João, Luiza Marek, Jozefowicz, Chang-Gyu, Jung, Martin, Kaatz, Nida, Kacar, Henry, Kanarek, Iva, Karlova, Alexander, Kastanayan, Jana, Kazandjieva, Johannes, Kern, Aharon, Kessel, Neena, Khanna, HeeJoo, Kim, Nancy, Kim, Sang-Ha, Kim, Tae-bum, Kim, Kulli, Kingo, Andreas, Kleinheinz, Janka, Komova, Evangelia, Kompoti, Tomas, Kopal, Peter, Kozub, Dorota, Krasowska, Beata, Krecisz, Burkhard, Kreft, Satsuki, Kubota, Hitoshi, Kudo, Teja, Kulkarni, Kanokvalai, Kulthanan, Akihiro, Kume, Maciej, Kupczyk, Edward, Lain, Bobby, Lanier, Hilde, Lapeere, Griselle Ortiz, Lasanta, Svetlana, Lazareva, Laura, Lazzeri, Dennis, Ledford, Donghun, Lee, Haur Yueh, Lee, Jeffrey, Leflein, Nicolas, Leitz, Nancy, Levin, Hermenio, Lima, Undine, Lippert, Brian, Lipson, Paula, Luna, Gabriel, Magarinos, Satyaprakash, Mahajan, Michail, Makris, Alejandro, Malbran, Ahmed Manjra, Manjra, Michael, Manning, Maria, Manrique, Adriana, Marcipar, Mariano, Marini, Veronique Del, Marmol, Jorge, Maspero, Tomoko, Matsuda, Jonathan, Matz, Marcus, Maurer, Wendy, McFalda, Anne, Mclaughlin, Iris, Medina, Rajesh Dutt, Mehta, Stephan, Meller, Steven, MELTZER, Raisa, Meshkova, Dorin, Mihalache, Francisco Javier, Miquel, Mourad, Mokni, J, Molhoek, Efrain, Montano, Sabine, Mueller, Javier Pedraz, Munoz, Toshikazu, Nagakura, Joanna, Narbutt, Ignasi Figueras, Nart, Ma. Lourdes M, Nebrida-Idea, Trong Hao, Nguyen, Johannes, Niesmann, Violeta Zaragoza, Ninet, Hiromitsu, Noguchi, Yuko Chinuki, Nomura, Roman, Nowicki, Tokuya, Omi, Robert, Onder, Ivan, Orojan, Francisco Javier, Ortiz de Frutos, Kim, Papp, Claudio, Parisi, Chun Wook, Park, Heungwoo, Park, Jungwon, Park, Young Min, Park, Viviana, Parra, Thierry, Passeron, Justine, Pasteur, Shivakumar, Patil, Vergil, Patrascu, Sylvia, Pauser, Anna Wojas, Pelc, Jonathan Grant, Peter, Wolfgang, Pfuetzner, Nicola, Pimpinelli, Andreas, Pinter, Cristian, Pizarro, Karel, Pizinger, Jarmila, Plutinska, Todor, Popov, Veronika, Popova, Marta Ferrer, Puga, Lara Ferrandiz, Pulido, Anca, Purcaru, Ulrike, Raap, Anna, Rajchel, John, Ramey, Ma Deanna Santos, Ramiscal, German Dario, Ramon, Syed, Rehman, Adam, Reich, Norbert, Reider, Krista, Ress, Dimitrios, Rigopoulos, Enrique, Rivas, Heike, Rockmann, Pierre-Paul, Roquet-Gravy, Menachem, Rottem, Vermen Verallo, Rowell, Franziska, Rueff, Juan Alberto Ruano, Ruiz, Juan, Russo, Ronald, Saff, Sarbjit, Saini, Maria, Salazar, Juan Francisco Silvestre, Salvador, Jorge, Sanchez, Florica, Sandru, Mark, Scarupa, Knut, Schaekel, Sibylle, Schliemann, Rik, Schrijvers, Beate, Schwarz, Andreas, Schwinn, Sudhir, Sekhsaria, Nilgun, Senturk, Seong Jun, Seo, Mercedes Rodriguez, Serna, Faradiba, Serpa, Paul A, Shapero, Eriko, Shinkawa, Jan-Christoph, Simon, Rodney, Sinclair, Ralfi, Singer, Dareen D, Siri, Karl, Sitz, Adam, Smialowski, Andrew, Smith, Morten, Soerensen, Wiebke, Sondermann, Haejun, Song, Dmitrii, Sonin, Weily, Soong, Daniel, Soteres, Maria, Staevska-Kotasheva, Petra, Staubach-Renz, Nisha Su Yien, Subash, Gordon, Sussman, Ake Svensson, Svensson, Ekaterini, Syrigou, Andrea, Szegedi, Jacek, Szepietowski, Shunsuke, Takahagi, Yuval, Tal, Neetu, Talreja, Wooi Chiang, Tan, Ricardo, Tan, Jyh Jong, Tang, Tonny, Tanus, Martha, Tarpay, Shang Ian, Tee, Craig, Teller, Florence, Tetart, Aurelie Du, Thanh, Suganthi, Thevarajah, Simon Francis, Thomsen, Carl, Thornblade, Milan, Tjioe, Alberto, Tolcachier, Celeste, Tolentino, Athanasios, Tsianakas, Ilia, Tsingov, Hamida, Turki, Olga, Ukhanova, Jens, Ulrich, Meltem, Uslu, Fernando, Valenzuela, Solange, Valle, Martijn, van Doorn, Jirina, Vankova, Suneel, Vartak, Christine, Vidouria, Sebastian, Volc, Gerald, Volcheck, Nicola, Wagner, Irena, Walecka-Herniczek, Penpun, Wattanakrai, Bettina, Wedi, Steven, Weinstein, Vesarat, Wessagowit, Hugh, Windom, Akiko, Yagami, Aisaku, Yamamoto, Shinichiro, Yasumoto, Young Min, Ye, Jose Cevallos, Yepez, Sang Woong, Youn, Hana, Zelenkova, Oleg, Ziganshin, Matthew, Zook, Maurer, Marcus, Ensina, Luis Felipe, Gimenez-Arnau, Ana Maria, Sussman, Gordon, Hide, Michihiro, Saini, Sarbjit, Grattan, Clive, Fomina, Daria, Rigopoulos, Dimitrios, Berard, Frederic, Canonica, Giorgio Walter, Rockmann, Heike, Szepietowski, Jacek C, Leflein, Jeffrey, Bernstein, Jonathan A, Peter, Jonny G, Kulthanan, Kanokvalai, Godse, Kiran, Ardusso, Ledit, Ukhanova, Olga, Staubach, Petra, Sinclair, Rodney, Gogate, Shaila, Thomsen, Simon Francis, Tanus, Tonny, Ye, Young Min, Burciu, Alis, Barve, Avantika, Modi, Darshna, Scosyrev, Emil, Hua, Eva, Letzelter, Kerstin, Varanasi, Vineeth, Patekar, Manmath, and Severin, Thomas
Published: 2024
Full Text: View/download PDF

9. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials

Author: Maurer, Marcus, primary, Ensina, Luis Felipe, additional, Gimenez-Arnau, Ana Maria, additional, Sussman, Gordon, additional, Hide, Michihiro, additional, Saini, Sarbjit, additional, Grattan, Clive, additional, Fomina, Daria, additional, Rigopoulos, Dimitrios, additional, Berard, Frederic, additional, Canonica, Giorgio Walter, additional, Rockmann, Heike, additional, Irani, Carla, additional, Szepietowski, Jacek C, additional, Leflein, Jeffrey, additional, Bernstein, Jonathan A, additional, Peter, Jonny G, additional, Kulthanan, Kanokvalai, additional, Godse, Kiran, additional, Ardusso, Ledit, additional, Ukhanova, Olga, additional, Staubach, Petra, additional, Sinclair, Rodney, additional, Gogate, Shaila, additional, Thomsen, Simon Francis, additional, Tanus, Tonny, additional, Ye, Young Min, additional, Burciu, Alis, additional, Barve, Avantika, additional, Modi, Darshna, additional, Scosyrev, Emil, additional, Hua, Eva, additional, Letzelter, Kerstin, additional, Varanasi, Vineeth, additional, Patekar, Manmath, additional, Severin, Thomas, additional, Rosana, Agondi, additional, Ahmed, Al Waily, additional, Fabio, Almerigogna, additional, Miguel Angel Tejedor, Alonso, additional, Alfred, Ammoury, additional, Eng Kim, Anne Goh, additional, Robert, Anolik, additional, Ledit, Ardusso, additional, Petr, Arenberger, additional, Nandini, AS, additional, Mohammad, Asefi, additional, Natalia, Astafieva, additional, Anil, Badhwar, additional, Esther Serra, Baldrich, additional, Christine, Bangert, additional, Annick, Barbaud, additional, Zsuzsanna, Bata-Csorgo, additional, Andrea, Bauer, additional, Frederic, Berard, additional, Beata, Bergler-Czop, additional, Gary D, Berman, additional, Jonathan, Bernstein, additional, Subhash Chandra, Bharija, additional, Ramesh M, Bhat, additional, Isabelle, Boccon-Gibod, additional, Ivan, Botev, additional, Knut, Brockow, additional, Philipp, Buck, additional, Paula, Busse, additional, Regis, Campos, additional, Giorgio Walter, Canonica, additional, Julia Maria Del, Carmen, additional, Jaime Del, Carpio, additional, Mamatha, Chadalavada, additional, Yoon-Seok, Chang, additional, Amarjit, Cheema, additional, Yi Hsing, Chen, additional, Yuko, Chinuki, additional, Soyun, Cho, additional, Jeong-Hee, Choi, additional, Chia-Yu, Chu, additional, Ronit, Confino, additional, Jonathan, Corren, additional, Roberta, Criado, additional, Claudia De La, Cruz, additional, David M, Cypcar, additional, Pramila, Daftary, additional, Inna, Danilycheva, additional, Kenneth, Dawes, additional, Michelle Joy, De Vera, additional, James, Deangelo, additional, Stefano, Del Giacco, additional, Diana, Deleanu, additional, John, Delgado, additional, Richard, DeMera, additional, Mohamed, Denguezli, additional, Heinrich, Dickel, additional, Le Huu, Doanh, additional, Sinan, Dogan, additional, Marie Sylvie, Doutre, additional, Anne Sophie, Dupond, additional, Anton, Edin, additional, Kent, EDWARD, additional, Swarna, Ekanayake-Bohling, additional, Daniel, Elbirt, additional, David, Elkayam, additional, Anne, Ellis, additional, Shaunagh, Emanuel, additional, Alexander, Emeliyanov, additional, Burhan, Engin, additional, Luis Felipe, Ensina, additional, Ignacio Antepara, Ercoreca, additional, Safiye, Ergun, additional, Jose Luis Lopez, Estebaranz, additional, Rustem, Fassakhov, additional, Daria, Fomina, additional, Linda, Ford, additional, Mariangela, Francomano, additional, Todd, Funkhouser, additional, Remi, Gagnon, additional, Ricardo, Galimberti, additional, Cesar Alberto, Galvan Calle, additional, Clovis, Galvao, additional, Gabriel, Gattolin, additional, Pierre-Dominique, Ghislain, additional, Ana Maria, Gimenez Arnau, additional, Elliot, Ginchansky, additional, Francoise, Giordano-Labadie, additional, Stanislav, Givirovsky, additional, Kiran, Godse, additional, Shaila, Gogate, additional, Alan, Goldsobel, additional, Francisca, Gomez, additional, Rene Maximiliano, Gomez, additional, Erika, Gonzalez, additional, Paula Ribo, Gonzalez, additional, Dimitar, Gospodinov, additional, Clive, Grattan, additional, Martine, Grosber, additional, Gary, Gross, additional, Francisco Jose Gomez, Guimera Martin-Neda, additional, Rolland, Gyulai, additional, Svetlana, Hadvabova, additional, Suzana Ljubojevic, Hadzavdic, additional, Hadi, Hamam, additional, Daniela, Hasicova, additional, Koremasa, Hayama, additional, Pravin, Hissaria, additional, Anna, Hjerppe, additional, Ivan, Hlinka, additional, Moises Labrador, Horrillo, additional, Connie, Hsu, additional, Yu-Huei, Huang, additional, Iftikhar, Hussain, additional, Atsuyuki, Igarashi, additional, Beata, IMKO-WALCZUK, additional, Huseyin Serhat, Inaloz, additional, Rossella, Intravaia, additional, Neal, Jain, additional, Sanjeev, Jain, additional, Thilo, Jakob, additional, Ruth Cerino, Javier, additional, Antonio, João, additional, Luiza Marek, Jozefowicz, additional, Chang-Gyu, Jung, additional, Martin, Kaatz, additional, Nida, Kacar, additional, Henry, Kanarek, additional, Iva, Karlova, additional, Alexander, Kastanayan, additional, Jana, Kazandjieva, additional, Johannes, Kern, additional, Aharon, Kessel, additional, Neena, Khanna, additional, HeeJoo, Kim, additional, Nancy, Kim, additional, Sang-Ha, Kim, additional, Tae-bum, Kim, additional, Kulli, Kingo, additional, Andreas, Kleinheinz, additional, Janka, Komova, additional, Evangelia, Kompoti, additional, Tomas, Kopal, additional, Peter, Kozub, additional, Dorota, Krasowska, additional, Beata, Krecisz, additional, Burkhard, Kreft, additional, Satsuki, Kubota, additional, Hitoshi, Kudo, additional, Teja, Kulkarni, additional, Kanokvalai, Kulthanan, additional, Akihiro, Kume, additional, Maciej, Kupczyk, additional, Edward, Lain, additional, Bobby, Lanier, additional, Hilde, Lapeere, additional, Griselle Ortiz, Lasanta, additional, Svetlana, Lazareva, additional, Laura, Lazzeri, additional, Dennis, Ledford, additional, Donghun, Lee, additional, Haur Yueh, Lee, additional, Jeffrey, Leflein, additional, Nicolas, Leitz, additional, Nancy, Levin, additional, Hermenio, Lima, additional, Undine, Lippert, additional, Brian, Lipson, additional, Paula, Luna, additional, Gabriel, Magarinos, additional, Satyaprakash, Mahajan, additional, Michail, Makris, additional, Alejandro, Malbran, additional, Ahmed Manjra, Manjra, additional, Michael, Manning, additional, Maria, Manrique, additional, Adriana, Marcipar, additional, Mariano, Marini, additional, Veronique Del, Marmol, additional, Jorge, Maspero, additional, Tomoko, Matsuda, additional, Jonathan, Matz, additional, Marcus, Maurer, additional, Wendy, McFalda, additional, Anne, Mclaughlin, additional, Iris, Medina, additional, Rajesh Dutt, Mehta, additional, Stephan, Meller, additional, Steven, MELTZER, additional, Raisa, Meshkova, additional, Dorin, Mihalache, additional, Francisco Javier, Miquel, additional, Mourad, Mokni, additional, J, Molhoek, additional, Efrain, Montano, additional, Sabine, Mueller, additional, Javier Pedraz, Munoz, additional, Toshikazu, Nagakura, additional, Joanna, Narbutt, additional, Ignasi Figueras, Nart, additional, Ma. Lourdes M, Nebrida-Idea, additional, Trong Hao, Nguyen, additional, Johannes, Niesmann, additional, Violeta Zaragoza, Ninet, additional, Hiromitsu, Noguchi, additional, Yuko Chinuki, Nomura, additional, Roman, Nowicki, additional, Tokuya, Omi, additional, Robert, Onder, additional, Ivan, Orojan, additional, Francisco Javier, Ortiz de Frutos, additional, Kim, Papp, additional, Claudio, Parisi, additional, Chun Wook, Park, additional, Heungwoo, Park, additional, Jungwon, Park, additional, Young Min, Park, additional, Viviana, Parra, additional, Thierry, Passeron, additional, Justine, Pasteur, additional, Shivakumar, Patil, additional, Vergil, Patrascu, additional, Sylvia, Pauser, additional, Anna Wojas, Pelc, additional, Jonathan Grant, Peter, additional, Wolfgang, Pfuetzner, additional, Nicola, Pimpinelli, additional, Andreas, Pinter, additional, Cristian, Pizarro, additional, Karel, Pizinger, additional, Jarmila, Plutinska, additional, Todor, Popov, additional, Veronika, Popova, additional, Marta Ferrer, Puga, additional, Lara Ferrandiz, Pulido, additional, Anca, Purcaru, additional, Ulrike, Raap, additional, Anna, Rajchel, additional, John, Ramey, additional, Ma Deanna Santos, Ramiscal, additional, German Dario, Ramon, additional, Syed, Rehman, additional, Adam, Reich, additional, Norbert, Reider, additional, Krista, Ress, additional, Dimitrios, Rigopoulos, additional, Enrique, Rivas, additional, Heike, Rockmann, additional, Pierre-Paul, Roquet-Gravy, additional, Menachem, Rottem, additional, Vermen Verallo, Rowell, additional, Franziska, Rueff, additional, Juan Alberto Ruano, Ruiz, additional, Juan, Russo, additional, Ronald, Saff, additional, Sarbjit, Saini, additional, Maria, Salazar, additional, Juan Francisco Silvestre, Salvador, additional, Jorge, Sanchez, additional, Florica, Sandru, additional, Mark, Scarupa, additional, Knut, Schaekel, additional, Sibylle, Schliemann, additional, Rik, Schrijvers, additional, Beate, Schwarz, additional, Andreas, Schwinn, additional, Sudhir, Sekhsaria, additional, Nilgun, Senturk, additional, Seong Jun, Seo, additional, Mercedes Rodriguez, Serna, additional, Faradiba, Serpa, additional, Paul A, Shapero, additional, Eriko, Shinkawa, additional, Jan-Christoph, Simon, additional, Rodney, Sinclair, additional, Ralfi, Singer, additional, Dareen D, Siri, additional, Karl, Sitz, additional, Adam, Smialowski, additional, Andrew, Smith, additional, Morten, Soerensen, additional, Wiebke, Sondermann, additional, Haejun, Song, additional, Dmitrii, Sonin, additional, Weily, Soong, additional, Daniel, Soteres, additional, Maria, Staevska-Kotasheva, additional, Petra, Staubach-Renz, additional, Nisha Su Yien, Subash, additional, Gordon, Sussman, additional, Ake Svensson, Svensson, additional, Ekaterini, Syrigou, additional, Andrea, Szegedi, additional, Jacek, Szepietowski, additional, Shunsuke, Takahagi, additional, Yuval, Tal, additional, Neetu, Talreja, additional, Wooi Chiang, Tan, additional, Ricardo, Tan, additional, Jyh Jong, Tang, additional, Tonny, Tanus, additional, Martha, Tarpay, additional, Shang Ian, Tee, additional, Craig, Teller, additional, Florence, Tetart, additional, Aurelie Du, Thanh, additional, Suganthi, Thevarajah, additional, Simon Francis, Thomsen, additional, Carl, Thornblade, additional, Milan, Tjioe, additional, Alberto, Tolcachier, additional, Celeste, Tolentino, additional, Athanasios, Tsianakas, additional, Ilia, Tsingov, additional, Hamida, Turki, additional, Olga, Ukhanova, additional, Jens, Ulrich, additional, Meltem, Uslu, additional, Fernando, Valenzuela, additional, Solange, Valle, additional, Martijn, van Doorn, additional, Jirina, Vankova, additional, Suneel, Vartak, additional, Christine, Vidouria, additional, Sebastian, Volc, additional, Gerald, Volcheck, additional, Nicola, Wagner, additional, Irena, Walecka-Herniczek, additional, Penpun, Wattanakrai, additional, Bettina, Wedi, additional, Steven, Weinstein, additional, Vesarat, Wessagowit, additional, Hugh, Windom, additional, Akiko, Yagami, additional, Aisaku, Yamamoto, additional, Shinichiro, Yasumoto, additional, Young Min, Ye, additional, Jose Cevallos, Yepez, additional, Sang Woong, Youn, additional, Hana, Zelenkova, additional, Oleg, Ziganshin, additional, and Matthew, Zook, additional
Published: 2023
Full Text: View/download PDF

10. Fungal sensitization in patients with severe atopic dermatitis as a distinct phenotype

Author: Valeriya Mikhaylova, Ekaterina Nikitina, Daria Fomina, Anton Chernov, and Marina Lebedkina
Abstract: Background. Many factors influence the development of atopic dermatitis (AD): genetic, environmental (including exposure to allergens), skin barrier damage, and activation of the T2-pathway immune response. Patients with AD, including those with severe disease, are prone to sensitization to various allergens, including fungal ones. Fungal sensitization (FS) promotes autoreactivity to the body's own structures due to shared epitopes with homologous fungal allergens. It can contribute to the development of allergic diseases, including AD, asthma, and rhinitis, as well as to their exacerbation and uncontrolled course. Since FS can be considered a factor aggravating AD, it is relevant to distinguish patients with FS and AD into a separate phenotype. Aim. To characterize the phenotype of patients with severe AD and FS using retrospective data analysis from a digital analytics platform in a real-world clinical setting. Materials and methods. A retrospective observational single-center study was conducted between 01.06.2017 and 01.07.2022. The study cohort included 88 patients with severe AD who were candidates for therapy or received treatment with either dupilumab or upadacitinib. FS was confirmed in 49 patients from the study group. Part of the cohort without FS (n=39) was used as a comparison group. Inclusion criteria: the age over 18 years old; severe AD (SCORAD40 points at the beginning of therapy); determination of specific immunoglobulin E to a panel of fungal allergens or individual fungi (or by the ImmunoCAP ISAC method to fungal allergen components). A digital analytics platform was used to generate primary data. Results. The phenotype of a patient with severe AD and confirmed FS was described. The patient profile is characterized by an extended sensitization spectrum (at least 34 allergen groups) with the most typical combination of pollen, epidermal, and FS. If there is a food allergy, it is of the classic "big eight" nature. Besides exacerbation of the skin disorder, its manifestations include angioedema of life-threatening localization and bronchospasm. Markers of T2 inflammation (high levels of immunoglobulin E and blood eosinophilia) are observed according to the test results, and the T2 endotype of allergy-related abnormalities is typical. Conclusion. Apparently, the presence of FS in patients with AD may exacerbate parenteral sensitization mechanisms, expanding its spectrum, including food allergens. Therefore, distinguishing the phenotype of severe AD with FS needs further detailing with a subsequent adaptation of monitoring and treatment methods of severe AD.
Published: 2022

11. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials

Author: Maurer, Marcus, Ensina, Luis Felipe, Gimenez-Arnau, Ana Maria, Sussman, Gordon, Hide, Michihiro, Saini, Sarbjit, Grattan, Clive, Fomina, Daria, Rigopoulos, Dimitrios, Berard, Frederic, Canonica, Giorgio Walter, Rockmann, Heike, Irani, Carla, Szepietowski, Jacek C, Leflein, Jeffrey, Bernstein, Jonathan A, Peter, Jonny G, Kulthanan, Kanokvalai, Godse, Kiran, Ardusso, Ledit, Ukhanova, Olga, Staubach, Petra, Sinclair, Rodney, Gogate, Shaila, Thomsen, Simon Francis, Tanus, Tonny, Ye, Young Min, Burciu, Alis, Barve, Avantika, Modi, Darshna, Scosyrev, Emil, Hua, Eva, Letzelter, Kerstin, Varanasi, Vineeth, Patekar, Manmath, Severin, Thomas, Rosana, Agondi, Ahmed, Al Waily, Fabio, Almerigogna, Miguel Angel Tejedor, Alonso, Alfred, Ammoury, Eng Kim, Anne Goh, Robert, Anolik, Ledit, Ardusso, Petr, Arenberger, Nandini, AS, Mohammad, Asefi, Natalia, Astafieva, Anil, Badhwar, Esther Serra, Baldrich, Christine, Bangert, Annick, Barbaud, Zsuzsanna, Bata-Csorgo, Andrea, Bauer, Frederic, Berard, Beata, Bergler-Czop, Gary D, Berman, Jonathan, Bernstein, Subhash Chandra, Bharija, Ramesh M, Bhat, Isabelle, Boccon-Gibod, Ivan, Botev, Knut, Brockow, Philipp, Buck, Paula, Busse, Regis, Campos, Giorgio Walter, Canonica, Irani, Carla, Julia Maria Del, Carmen, Jaime Del, Carpio, Mamatha, Chadalavada, Yoon-Seok, Chang, Amarjit, Cheema, Yi Hsing, Chen, Yuko, Chinuki, Soyun, Cho, Jeong-Hee, Choi, Chia-Yu, Chu, Ronit, Confino, Jonathan, Corren, Roberta, Criado, Claudia De La, Cruz, David M, Cypcar, Pramila, Daftary, Inna, Danilycheva, Kenneth, Dawes, Michelle Joy, De Vera, James, Deangelo, Stefano, Del Giacco, Diana, Deleanu, John, Delgado, Richard, DeMera, Mohamed, Denguezli, Heinrich, Dickel, Le Huu, Doanh, Sinan, Dogan, Marie Sylvie, Doutre, Anne Sophie, Dupond, Anton, Edin, Kent, EDWARD, Swarna, Ekanayake-Bohling, Daniel, Elbirt, David, Elkayam, Anne, Ellis, Shaunagh, Emanuel, Alexander, Emeliyanov, Burhan, Engin, Luis Felipe, Ensina, Ignacio Antepara, Ercoreca, Safiye, Ergun, Jose Luis Lopez, Estebaranz, Rustem, Fassakhov, Daria, Fomina, Linda, Ford, Mariangela, Francomano, Todd, Funkhouser, Remi, Gagnon, Ricardo, Galimberti, Cesar Alberto, Galvan Calle, Clovis, Galvao, Gabriel, Gattolin, Pierre-Dominique, Ghislain, Ana Maria, Gimenez Arnau, Elliot, Ginchansky, Francoise, Giordano-Labadie, Stanislav, Givirovsky, Kiran, Godse, Shaila, Gogate, Alan, Goldsobel, Francisca, Gomez, Rene Maximiliano, Gomez, Erika, Gonzalez, Paula Ribo, Gonzalez, Dimitar, Gospodinov, Clive, Grattan, Martine, Grosber, Gary, Gross, Francisco Jose Gomez, Guimera Martin-Neda, Rolland, Gyulai, Svetlana, Hadvabova, Suzana Ljubojevic, Hadzavdic, Hadi, Hamam, Daniela, Hasicova, Koremasa, Hayama, Pravin, Hissaria, Anna, Hjerppe, Ivan, Hlinka, Moises Labrador, Horrillo, Connie, Hsu, Yu-Huei, Huang, Iftikhar, Hussain, Atsuyuki, Igarashi, Beata, IMKO-WALCZUK, Huseyin Serhat, Inaloz, Rossella, Intravaia, Neal, Jain, Sanjeev, Jain, Sanjeev, Jain, Thilo, Jakob, Ruth Cerino, Javier, Antonio, João, Luiza Marek, Jozefowicz, Chang-Gyu, Jung, Martin, Kaatz, Nida, Kacar, Henry, Kanarek, Iva, Karlova, Alexander, Kastanayan, Jana, Kazandjieva, Johannes, Kern, Aharon, Kessel, Neena, Khanna, HeeJoo, Kim, Nancy, Kim, Sang-Ha, Kim, Tae-bum, Kim, Kulli, Kingo, Andreas, Kleinheinz, Janka, Komova, Evangelia, Kompoti, Tomas, Kopal, Peter, Kozub, Dorota, Krasowska, Beata, Krecisz, Burkhard, Kreft, Satsuki, Kubota, Hitoshi, Kudo, Teja, Kulkarni, Kanokvalai, Kulthanan, Akihiro, Kume, Maciej, Kupczyk, Edward, Lain, Bobby, Lanier, Hilde, Lapeere, Griselle Ortiz, Lasanta, Svetlana, Lazareva, Laura, Lazzeri, Dennis, Ledford, Donghun, Lee, Haur Yueh, Lee, Jeffrey, Leflein, Nicolas, Leitz, Nancy, Levin, Hermenio, Lima, Undine, Lippert, Brian, Lipson, Paula, Luna, Gabriel, Magarinos, Satyaprakash, Mahajan, Michail, Makris, Alejandro, Malbran, Ahmed Manjra, Manjra, Michael, Manning, Maria, Manrique, Adriana, Marcipar, Mariano, Marini, Veronique Del, Marmol, Jorge, Maspero, Tomoko, Matsuda, Jonathan, Matz, Marcus, Maurer, Wendy, McFalda, Anne, Mclaughlin, Iris, Medina, Rajesh Dutt, Mehta, Stephan, Meller, Steven, MELTZER, Raisa, Meshkova, Dorin, Mihalache, Francisco Javier, Miquel, Mourad, Mokni, J, Molhoek, Efrain, Montano, Sabine, Mueller, Javier Pedraz, Munoz, Toshikazu, Nagakura, Joanna, Narbutt, Ignasi Figueras, Nart, Ma. Lourdes M, Nebrida-Idea, Trong Hao, Nguyen, Johannes, Niesmann, Violeta Zaragoza, Ninet, Hiromitsu, Noguchi, Yuko Chinuki, Nomura, Roman, Nowicki, Tokuya, Omi, Robert, Onder, Ivan, Orojan, Francisco Javier, Ortiz de Frutos, Kim, Papp, Claudio, Parisi, Chun Wook, Park, Heungwoo, Park, Jungwon, Park, Young Min, Park, Viviana, Parra, Thierry, Passeron, Justine, Pasteur, Shivakumar, Patil, Vergil, Patrascu, Sylvia, Pauser, Anna Wojas, Pelc, Jonathan Grant, Peter, Wolfgang, Pfuetzner, Nicola, Pimpinelli, Andreas, Pinter, Cristian, Pizarro, Karel, Pizinger, Jarmila, Plutinska, Todor, Popov, Veronika, Popova, Marta Ferrer, Puga, Lara Ferrandiz, Pulido, Anca, Purcaru, Ulrike, Raap, Anna, Rajchel, John, Ramey, Ma Deanna Santos, Ramiscal, German Dario, Ramon, Syed, Rehman, Adam, Reich, Norbert, Reider, Krista, Ress, Dimitrios, Rigopoulos, Enrique, Rivas, Heike, Rockmann, Pierre-Paul, Roquet-Gravy, Menachem, Rottem, Vermen Verallo, Rowell, Franziska, Rueff, Juan Alberto Ruano, Ruiz, Juan, Russo, Ronald, Saff, Sarbjit, Saini, Maria, Salazar, Juan Francisco Silvestre, Salvador, Jorge, Sanchez, Florica, Sandru, Mark, Scarupa, Knut, Schaekel, Sibylle, Schliemann, Rik, Schrijvers, Beate, Schwarz, Andreas, Schwinn, Sudhir, Sekhsaria, Nilgun, Senturk, Seong Jun, Seo, Mercedes Rodriguez, Serna, Faradiba, Serpa, Paul A, Shapero, Eriko, Shinkawa, Jan-Christoph, Simon, Rodney, Sinclair, Ralfi, Singer, Dareen D, Siri, Karl, Sitz, Adam, Smialowski, Andrew, Smith, Morten, Soerensen, Wiebke, Sondermann, Haejun, Song, Dmitrii, Sonin, Weily, Soong, Daniel, Soteres, Maria, Staevska-Kotasheva, Petra, Staubach-Renz, Nisha Su Yien, Subash, Gordon, Sussman, Ake Svensson, Svensson, Ekaterini, Syrigou, Andrea, Szegedi, Jacek, Szepietowski, Shunsuke, Takahagi, Yuval, Tal, Neetu, Talreja, Wooi Chiang, Tan, Ricardo, Tan, Jyh Jong, Tang, Tonny, Tanus, Martha, Tarpay, Shang Ian, Tee, Craig, Teller, Florence, Tetart, Aurelie Du, Thanh, Suganthi, Thevarajah, Simon Francis, Thomsen, Carl, Thornblade, Milan, Tjioe, Alberto, Tolcachier, Celeste, Tolentino, Athanasios, Tsianakas, Ilia, Tsingov, Hamida, Turki, Olga, Ukhanova, Jens, Ulrich, Meltem, Uslu, Fernando, Valenzuela, Solange, Valle, Martijn, van Doorn, Jirina, Vankova, Suneel, Vartak, Christine, Vidouria, Sebastian, Volc, Gerald, Volcheck, Nicola, Wagner, Irena, Walecka-Herniczek, Penpun, Wattanakrai, Bettina, Wedi, Steven, Weinstein, Vesarat, Wessagowit, Hugh, Windom, Akiko, Yagami, Aisaku, Yamamoto, Shinichiro, Yasumoto, Young Min, Ye, Jose Cevallos, Yepez, Sang Woong, Youn, Hana, Zelenkova, Oleg, Ziganshin, and Matthew, Zook
Abstract: Many patients with chronic spontaneous urticaria (CSU) do not achieve complete control of their symptoms with current available treatments. In a dose-finding phase 2b study, ligelizumab improved urticaria symptoms in patients with H1-antihistamine (H1-AH) refractory CSU. Here, we report the efficacy and safety outcomes from two ligelizumab phase 3 studies.
Published: 2024
Full Text: View/download PDF

12. The reduction of peripheral blood Treg differentiated fractions and the CD25 expression in Patients with Graves' disease after Radioactive Iodine Therapy

Author: Margarita Dudina, Andrey Savchenko, Dogadin Sergey A., Borisov Alexander G., Vasiliy Belenyuk, and Daria Fomina
Subjects: General Medicine
Published: 2023

13. The Reactive Oxygen Species Level of Blood Monocytes in Patients with Graves' Disease After Radioiodine Therapy

Author: Daria Fomina, Dogadin Sergey A., Andrey Savchenko, Margarita Dudina, and Ivan Gvozdev
Subjects: General Medicine
Published: 2023

14. SARS-CoV-2-NEUTRALISING MONOCLONAL ANTIBODIES: MECHANISM OF ACTION AND RESEARCH RESULTS

Author: Ekaterina Alexeeva, Daria Fomina, Marina Lebedkina, and Alexander Karaulov
Subjects: Pediatrics, Perinatology and Child Health
Abstract: The COVID-19 vaccination has become a way of effective prevention of the decease for most people globally. However, there is a cohort of patients who are not able to form a full-fledged immune response due to primary or secondary immunodeficiency conditions caused by genetic disorders, severe course of chronic diseases, due to their age or the use of drugs that suppress the immune response. The use of monoclonal viral antibodies for immunocompromised patients is the most efficient method of pre- and post-contact and even long-term prevention, as well as the treatment of coronavirus infection. Monoclonal antibodies are obtained from B-lymphocytes of patients recovered from COVID-19. As a result of further modification aimed at increasing of the efficiency and reducing the risk of unwanted phenomena in the use, the virus-neutralizing recombinant monoclonal antibodies of the IgG1 class were designed to implement preventive and therapeutic schemes for COVID-19. Treatment of a new coronavirus infection with drugs with direct etiotropic action is most effective when prescribing in the early stages of the disease, which is especially relevant in patients at risk for a severe/critical clinical course of the disease and can be performed as outpatient clinical procedures. The article analyzes the results of clinical studies of efficacy and safety of mono- and combined drugs of monoclonal antibodies to SARS-CoV-2 in patients with the new coronavirus infection, as well as potential possibilities for their use for the treatment of COVID-19 caused by the new SARS-CoV-2 strains with multiple mutations on the example of the Omicron strain.
Published: 2022

15. The influence of affluence on prosocial behavior

Author: Daria Fomina, Amy Goltermann, Claire Elise Berner, Stephen Spivack, Theadora Bulajic, Jennifer Freda, Amelia Karim, Helena Julia Torres-Siclait, Jinge Ren, Alexis Egazarian, Jennifer Marina Perez, Stephanie Devli, Victoria Tong, Andrea Poinçot-Leopardi, Sam Golden, Pranav Lowe, Jonah Zinn, Sagar Shah, Garrett Ienner, Alon Florentin, Lucy Cranmer, John Yaurimo, Morolayo Ayodele, Barbara Angie Clergé Boirond, Naud Jacob Zwier Veldhoen, Sahar Hafezi, Dylan Tossavainen, Huidi Yang, Nkiruka Olivia Marie Amu, Shelby McClelland, and Pascal Wallisch
Abstract: Popular wisdom has it that excessive material wealth leads to decreased prosocial behavior. This notion has empirical support in the literature, but there are open questions about how strong, specific, and general this effect is. Here, we aimed to test the hypothesis that increased SES is associated with decreased prosocial behavior in a high-powered laboratory task. We find thatthere are no statistically significant differences in generosity as a function of social class. However, there are subtle - yet statistically significant - patterns linking SES and dark triad personality traits. We conclude that the relationship between SES and social behavior isconsiderably more nuanced than commonly believed.
Published: 2023

16. Validating Instruments to Screen for Psychopathy in a Non-Institutionalized Population

Author: Theadora Bulajic, Nkiruka Olivia Marie Amu, Jinge Ren, Claire Elise Berner, Daria Fomina, Sagar Shah, John Yaurimo, Morolayo Ayodele, Jonah Zinn, Sam Golden, Shelby McClelland, Jennifer Marina Perez, Pranav Lowe, Amy Goltermann, Sahar Hafezi, Alexis Egazarian, Huidi Yang, Victoria Tong, Dylan Tossavainen, Lucy Cranmer, Alon Florentin, Naud Jacob Zwier Veldhoen, Jennifer Freda, Stephanie Devli, Amelia Karim, Barbara Angie Clergé Boirond, Helena Julia Torres-Siclait, Garrett Ienner, Andrea Poinçot-Leopardi, Stephen Spivack, and Pascal Wallisch
Abstract: We wanted to validate commonly used instruments to measure psychopathic tendencies in a college student population. To do so, we administered both the “Dark Triad Dirty Dozen” and the "Levenson Self-Report Psychopathy scale" to a high-powered sample of college students. Participants also performed a social discounting task to measure generosity. We correlated all of these measures and found that both instruments correlate well and negatively with generosity. We take these findings to indicate that both instruments are valid measures of psychopathic tendencies in non-institutionalized populations.
Published: 2023

17. Chronic inducible urticaria: Clinical presentation, diagnosis, and management

Author: Pelin Kuteyla Can, Daria Fomina, and Emek Kocaturk
Subjects: immune system diseases, parasitic diseases, skin and connective tissue diseases
Abstract: Chronic inducible urticaria (CIndU) is a subtype of chronic urticaria characterized by recurrent itchy wheals and/or angioedema for more than 6 weeks. CIndU has a longer disease duration than chronic spontaneous urticaria (CSU) and wheals are shorter lasting than CSU. CIndU incudes physical and non-physical urticaria. Triggers and diagnosis of subtypes of CIndU differ from each other. Patient education for avoiding triggers is an important aspect of the treatment of CIndU. There is no significant difference in the treatment approach for CIndU and CSU. In this article, we have discussed different types of CIndU, their clinical features, diagnosis, and management.
Published: 2022

18. Vaccination against COVID-19 for patients with primary immunodeficiency and hereditary angioedema: the position paper of the Russian Association of Allergology, Clinical Immunology, and the National Association of Experts in Primary Immunodeficiencies

Author: Elena A. Latysheva, Anna Shcherbina, Tatiana V. Latysheva, Musa R. Khaitov, Daria Fomina, Natalya I. Ilyina, Evgeniya V. Nazarova, Irina Kondratenko, and Irina A. Manto
Subjects: Pediatrics, medicine.medical_specialty, Angioedema, business.industry, Context (language use), General Medicine, medicine.disease, medicine.disease_cause, Vaccination, Hereditary angioedema, Pandemic, Primary immunodeficiency, Medicine, Position paper, medicine.symptom, business, Coronavirus
Abstract: Since the end of 2019, the whole world has been seized by the COVID-19 pandemic caused by the SARS-CoV2 virus. To date, the infection has led to more than 4 million deaths worldwide, and to more than 140 thousand deaths in Russia. COVID-19 (abbreviation for COronaVIrus Disease 2019) is a potentially severe acute respiratory infection caused by the SARS-CoV-2 coronavirus (2019-nCoV). Vaccination against COVID-19 plays a key role in stopping the pandemic. According to existing experience in infections prevention, mass vaccination will reduce the virus’s expansion and the risk of vaccine-resistant strains’ development. In the context of the COVID-19 the question of the feasibility and safety of vaccination of patients with Primary Immunodeficiency and Hereditary Angioedema arises. The Russian Association of Allergists and Clinical Immunologists and the National Association of Experts in Primary Immunodeficiencies have developed and approved a position paper on vaccination of patients with Primary Immunodeficiency and Hereditary Angioedema against COVID-19. This position paper provides answers to key questions regarding the vaccination of patients with these diseases.
Published: 2021

19. Adrenaline autoinjector is under-prescribed in typical cold urticaria patients living in tropical climate countries

Author: Mojca Bizjak, Mitja Košnik, Dejan Dinevski, Simon Francis Thomsen, Daria Fomina, Elena Borzova, Kanokvalai Kulthanan, Raisa Meshkova, FernandoM Aarestrup, Dalia Melina Ahsan, Mona Al-Ahmad, Sabine Altrichter, Andrea Bauer, Maxi Brockstädt, Célia Costa, Semra Demir, Roberta Fachini Criado, Luis Felipe Ensina, Asli Gelincik, Ana Maria Giménez-Arnau, Margarida Gonçalo, Maia Gotua, Jesper Grønlund Holm, Naoko Inomata, Alicja Kasperska-Zajac, Maryam Khoshkhui, Aliya Klyucharova, Emek Kocatürk, Rongbiao Lu, Michael Makris, Natalya Maltseva, Maria Pasali, Marisa Paulino, David Pesqué, Jonny Peter, German Dario Ramón, Carla Ritchie, Solange Oliveira Rodrigues Valle, Michael Rudenko, Agnieszka Sikora, Nicola Wagner, Paraskevi Xepapadaki, Xiaoyang Xue, Zuotao Zhao, Dorothea Terhorst-Molawi, and Marcus Maurer
Subjects: General Medicine
Published: 2022

20. Comorbidity defines asthmatic patients' risk of COVID-19 hospitalization: A global perspective

Author: Chrysanthi Skevaki, R. Sharon Chinthrajah, Daria Fomina, Gernot Rohde, Shu Cao, Ziyuan He, Sofia Serdotetskova, Christian Seidemann, Achim Grünewaldt, Abisha Vengadeswaran, Min Xie, Antonina Karsonova, Alexander Karaulov, Kari C. Nadeau, Ho-Ryun Chung, and Harald Renz
Subjects: Immunology, Immunology and Allergy
Abstract: The global epidemiology of asthma among patients with coronavirus disease 2019 (COVID-19) presents striking geographic differences, defining prevalence zones of high and low co-occurrence of asthma and COVID-19.We aimed to compare asthma prevalence among hospitalized patients with COVID-19 in major global hubs across the world by applying common inclusion criteria and definitions.We built a network of 6 academic hospitals in Stanford (Stanford University)/the United States; Frankfurt (Goethe University), Giessen (Justus Liebig University), and Marburg (Philipps University)/Germany; and Moscow (Clinical Hospital 52 in collaboration with Sechenov University)/Russia. We collected clinical and laboratory data for patients hospitalized due to COVID-19.Asthmatic individuals were overrepresented among hospitalized patients with COVID-19 in Stanford and underrepresented in Moscow and Germany as compared with their prevalence among adults in the local community. Asthma prevalence was similar among patients hospitalized in an intensive care unit and patients hospitalized in other than an intensive care unit, which implied that the risk for development of severe COVID-19 was not higher among asthmatic patients. The numbers of males and comorbidities were higher among patients with COVID-19 in the Stanford cohort, and the most frequent comorbidities among these patients with asthma were other chronic inflammatory airway disorders such as chronic obstructive pulmonary disease.The observed disparity in COVID-19-associated risk among asthmatic patients across countries and continents is connected to the varying prevalence of underlying comorbidities, particularly chronic obstructive pulmonary disease.
Published: 2022

21. Comorbidity defines risk of asthmatics for COVID-19 hospitalization: a global perspective

Author: Chrysanthi Skevaki, Sharon Chinthrajah, Daria Fomina, Gernot Rohde, Shu Cao, Ziyuan He, Sofia Serdotetskova, Christian Seidemann, Achim Grünewaldt, Abisha Vengadeswaran, Min Xie, Antonina Karsonova, Alexander Karaulov, Kari Nadeau, Ho-Ryun Chung, and Harald Renz
Abstract: Background: The global epidemiology of asthma among COVID-19 patients presents striking geographic differences defining high and low [asthma and COVID-19] co-occurrence prevalence zones (1). The objective of the present study was to compare asthma prevalence among hospitalized COVID-19 patients in major global hubs across the world with the application of common inclusion criteria and definitions. Methods: We built a network of six academic hospitals in Stanford (Stanford University)/USA, Frankfurt (Goethe University), Giessen (Justus Liebig University) and Marburg (Philipps University)/Germany, and Moscow (Clinical Hospital 52 in collaboration with Sechenov University)/Russia. We collected clinical and laboratory data for patients hospitalized due to COVID-19. Comorbidities reported were based on the 2020 International Classification of Diseases-10th Revision codes. Results: Asthmatics were overrepresented among hospitalized COVID-19 patients in Stanford and underrepresented in Moscow and Germany as compared to the prevalence among adults in the local community. Asthma prevalence was similar among ICU and hospital non-ICU patients, which implied that the risk for developing severe COVID-19 was not higher among asthmatics. The number of males and comorbidities was higher among COVID-19 patients in the Stanford cohort, and the most frequent comorbidities among these asthma patients were other chronic inflammatory airway disorders such as chronic obstructive pulmonary disease (COPD). Conclusion: Observed disparity in COVID-19-associated risk among asthmatics across countries and continents is connected to varying prevalence of underlying comorbidities, particularly COPD. Public health policies in the future will need to consider comorbidities with an emphasis on COPD for prioritization of vaccination and preemptive treatment.
Published: 2022

22. Decrease the functional activity of adaptive immunity cells one month after radioiodine therapy for Graves' diseaseDecrease the functional activity of adaptive immunity cells one month after radioiodine therapy for Graves' disease

Author: Andrey Savchenko, Margarita Dudina, Sergey A. Dogadin, Alexandr Borisov, Daria Fomina, and Vasiliy Belenyuk
Published: 2022

23. Total IgE levels are linked to the course of chronic spontaneous urticaria during pregnancy

Author: Emek Kocatürk, Simon Francis Thomsen, Mona Al-Ahmad, Ana M. Gimenez Arnau, Niall Conlon, Ekin Şavk, Roberta Fachini Jardim Criado, Inna Danilycheva, Daria Fomina, Maryam Khoshkhui, Aslı Gelincik, Ece Nur Yüksel, Semra Ertan, Luis Felipe Ensina, Alicja Kasperska-Zajac, Michael Rudenko, Andrea Bauer, Iris V. Medina, and Marcus Maurer
Subjects: Immunology and Allergy
Published: 2022

24. The Benefit of Complete Response to Treatment in Patients With Chronic Spontaneous Urticaria—CURE Results

Author: Pavel Kolkhir, Pedro A. Laires, Pascale Salameh, Riccardo Asero, Mojca Bizjak, Mitja Košnik, Joachim Dissemond, Martijn van Doorn, Tomasz Hawro, Alicja Kasperska-Zajac, Magdalena Zajac, Emek Kocatürk, Jonny Peter, Claudio A.S. Parisi, Carla A. Ritchie, Kanokvalai Kulthanan, Papapit Tuchinda, Daria Fomina, Elena Kovalkova, Maryam Khoshkhui, Samaneh Kouzegaran, Niki Papapostolou, Aurélie Du-Thanh, Akiko Kamegashira, Raisa Meshkova, Alexander Vitchuk, Andrea Bauer, Clive Grattan, Petra Staubach, Laurence Bouillet, Ana M. Giménez-Arnau, Marcus Maurer, Karsten Weller, and Dermatology
Subjects: Quality of life, Patient-reported outcomes, CURE registry, Medizin, Immunology and Allergy, Complete control/complete response to treatment, Chronic spontaneous urticaria
Abstract: Background and Objective: Chronic spontaneous urticaria (CSU) is a distressing disease. We report real-world data from the global Chronic Urticaria Registry (CURE) about associations between various CSU states and sleep impairment, plus important health-related quality-of-life (HRQoL) outcomes and compared different methods to assess CSU states. Methods: CURE data were collected at baseline and 6-monthly follow-ups (FU). Assessments included CSU states using the Urticaria Control Test (UCT), weekly Urticaria Activity Score (UAS7), and Physician Global Assessment (PhyGA) of treatment response. Complete response to treatment (CR, UAS7 = 0), complete control of disease (CC, UCT = 16), and PhyGA = CR were assessed, plus the Dermatology Life Quality Index and the Chronic Urticaria Quality-of-Life Questionnaire (CU-Q2oL) sleep domain. Results: Overall, 2078 patients were included. At baseline, 9.8%, 17.9%, and 42.3% of patients had UCT = 16, UAS7 = 0, or PhyGA = CR, respectively, which increased at FU1 and FU2. Patients with higher UCT scores had better sleep and HRQoL. The presence of angioedema without wheals, episodic disease, omalizumab treatment, and male sex were associated with CC (P
Published: 2023

25. Is There Any Relationship Between Chronic Urticaria, Its Severity and Alexithymia?

Author: Luis Miguel Escalante Fiallos, Ivan Cherrez Ojeda, Simon Thomsen, Ana Giménez-Arnau, Jennifer Astrup Sørensen, Kiran Godse, Carole Guillet, Astrid Karolina Maldonado Apolo, Gonzalo Chorzepa, Blanca Morfin-Maciel, Jose Ignacio Larco Sousa, Erika De Arruda Chaves, Abhishek De, Daria Fomina, Anant Patil, Roberta Jardim Criado, Luis Felipe Ensina, Solange Valle, Rosana Agondi, Herberto Chong Neto, Nelson Rosario, German Dario Ramon, Marco Faytong-Haro, Isabel Ogueta, Ivan Tinoco Moran, Jaime Cárdenas, Mariana Tinoco Chabla, Sandy Aguilar Gavilanes, Victor Estuardo Farinango Salazar, Silvio Duran Huacon, Pablo Maldonado Donoso, Nelson Muñoz, Johnny Gallardo Gallardo, Damelis Martinez Letterni, and Karla Robles-Velasco
Subjects: Immunology, Immunology and Allergy
Published: 2023

26. The global burden of chronic urticaria for the patient and society*

Author: Jonathan A. Bernstein, Moshe Ben-Shoshan, Ibrahim S Nasr, Kanokvalai Kulthanan, Jonny Peter, Michihiro Hide, Daria Fomina, Margarida Gonçalo, Clive Grattan, Ana Giménez-Arnau, Maryam Khoshkhui, Ingrid E Medina, Ma'moon M Al-Ahmad, Kiran Godse, Petra Staubach, Marcus Maurer, Luis Felipe Ensina, L Wang, Emek Kocatürk, Constance H. Katelaris, Cesar A Galvàn, and Karsten Weller
Subjects: Pediatrics, medicine.medical_specialty, Urticaria, Omalizumab, Dermatology, Disease, 030207 dermatology & venereal diseases, 03 medical and health sciences, Indirect costs, 0302 clinical medicine, Quality of life, medicine, Humans, Chronic Urticaria, Depression (differential diagnoses), business.industry, Urticària -- Tractament, Dermatology Life Quality Index, Middle Aged, Salut pública, Europe, Sexual dysfunction, Qualitat de vida, Chronic Disease, Presenteeism, Quality of Life, Indicadors econòmics, Female, medicine.symptom, business, medicine.drug
Abstract: Chronic urticaria (CU) affects about 1% of the world population of all ages, mostly young and middle-aged women. It usually lasts for several years (> 1 year in 25-75% of patients) and often takes > 1 year before effective management is implemented. It presents as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) or both in the same person. More than 25% of cases are resistant to H1 -antihistamines, even at higher doses, and third- and fourth-line therapies (omalizumab and ciclosporin) control the disease only in two-thirds of H1 -antihistamine-resistant patients. Here we review the impact of CU on different aspects of patients' quality of life and the burden of this chronic disease for the patient and society. CU may have a strong impact on health-related quality of life (HRQoL), particularly when CSU is associated with angio-oedema and/or CIndU (Dermatology Life Quality Index > 10 in 30% of patients). Comorbidities, such as anxiety and depression, which are present in more than 30% of patients with CSU, compound HRQoL impairment. Severe pruritus and the unpredictable occurrence of weals and angio-oedema are responsible for sleep disorders; sexual dysfunction; limitations on daily life, work and sports activities; interfering with life within the family and in society; and patients' performance at school and work (6% absenteeism and 25% presenteeism). Apart from treatment costs, with annual values between 900 and 2400 purchasing power parity dollars (PPP$) in Europe and the USA, CU is associated with a high consumption of medical resources and other indirect costs, which may reach a total annual cost of PPP$ 15 550.
Published: 2020

27. Temporal Clinical and Laboratory Response to Interleukin-6 Receptor Blockade With Tocilizumab in 89 Hospitalized Patients With COVID-19 Pneumonia

Author: Alexander Karaulov, Anton A. Chernov, Inna V. Samsonova, Irina P. Beloglazova, Daria Fomina, M. A. Lysenko, Zinaida Yu. Mutovina, Nataliya G. Poteshkina, and Tat'yana S. Kruglova
Subjects: lcsh:Immunologic diseases. Allergy, Microbiology (medical), medicine.medical_specialty, medicine.medical_treatment, Immunology, Gastroenterology, chemistry.chemical_compound, tocilizumab, Tocilizumab, Internal medicine, lcsh:Pathology, Immunology and Allergy, Medicine, pneumonia, Interleukin 6, Molecular Biology, Mechanical ventilation, IL-6, biology, business.industry, SARS-CoV-2, C-reactive protein, medicine.disease, Blockade, Pneumonia, Infectious Diseases, chemistry, cytokine storm, biology.protein, Lymphocytopenia, lcsh:RC581-607, business, Cytokine storm, Covid-19, lcsh:RB1-214, Research Article
Abstract: Background: Pandemic COVID-19 pneumonia due to SARS-2 is an important cause of morbidity and mortality. Emerging evidence links poor outcomes to an inflammatory cytokine storm.Methods: We treated 89 hospitalized patients with COVID-19 pneumonia and heightened systemic inflammation (elevated serum C reactive protein and interleukin-6 levels) with an infusion of tocilizumab (TCZ), a human monoclonal IgG1 antibody to the interleukin-6 receptor.Results: Clinical and laboratory evidence of improvement was evident when baseline and 1-2-day post-infusion indices were compared. Among the 72 patients receiving supplemental oxygen without mechanical ventilation, severity of condition on the NEWS2 scale scores fell from 5 to 2 (P30 mg/L) and low lymphocyte counts (
Published: 2020

28. Treatment patterns and outcomes in patients with chronic urticaria during pregnancy: Results of PREG-CU, a UCARE Study

Author: Emek Kocatürk, Mona Al‐Ahmad, Karoline Krause, Ana M. Gimenez‐Arnau, Simon Francis Thomsen, Niall Conlon, Alexander Marsland, Ekin Savk, Roberta F. Criado, Inna Danilycheva, Daria Fomina, Kiran Godse, Maryam Khoshkhui, Aslı Gelincik, Ece Nur Degirmentepe, Semra Demir, Luis Felipe Ensina, Alicja Kasperska‐Zajac, Michael Rudenko, Solange Valle, Iris Medina, Andrea Bauer, Zuotao Zhao, Petra Staubach, Laurence Bouillet, Özlem Su Küçük, Arzu Baygül, Marcus Maurer, and SU KÜÇÜK, ÖZLEM
Subjects: Infectious Diseases, Results of PREG-CU, a UCARE study-, JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022 [Kocatuerk E., Al-Ahmad M., Krause K., Gimenez-Arnau A. M. , Thomsen S. F. , Conlon N., Marsland A., BOZKURT ŞAVK E., Criado R. F. , Danilycheva I., et al., -Treatment patterns and outcomes in patients with chronic urticaria during pregnancy], Dermatology
Abstract: Introduction: Chronic urticaria (CU) is a common disease that primarily affects females. Although commonly encountered, there is little data on how pregnancy interact with CU. We analysed treatment use by CU patients before, during and after pregnancy as well as outcomes of pregnancy. Material and Methods: PREG-CU was a prospective and retrospective, international, multicentre, study of the Urticaria Centers of Reference and Excellence (UCARE) network. Data were collected via a 47-item-questionnaire completed by CU patients who became pregnant during their disease course. Results: Questionnaires from 288 CU patients from 13 countries were analysed. During pregnancy, most patients (60%) used urticaria medication (standard dose second generation H1-antihistamines [SD-sgAH] (35.1%), first generation H1-antihistamines (7.6%), high-dose sgAH (5.6%), and omalizumab (5.6%). The preterm birth rate was 10.2%, and preterm rates of patients who did and did not receive treatment during pregnancy were similar (11.6% vs 8.7%). Emergency referrals for CU and twin birth were risk factors for preterm birth. The caesarean delivery rate was 51.3%. More than 90% of new-borns. were healthy at birth. There was no link between any patient or disease characteristics or treatments and medical problems at birth. Eight of 10 (78.8%) women with CU breastfed their babies and most (54.3%) used urticaria medication while breastfeeding. Conclusion: Rates of preterm births and medical problems of new-borns in patients with CU were similar to population norms and not linked to treatment used during pregnancy. Emergency referrals increase risk of preterm birth and emphasizes the importance of urticaria control during pregnancy.
Published: 2022

29. Reply to 'Is anti-TPO IgG and total IgE clinically useful for the detection of autoimmune chronic spontaneous urticaria'?

Author: Pavel Kolkhir, Elena Kovalkova, Anton Chernov, Inna Danilycheva, Karoline Krause, Merle Sauer, Andrey Shulzhenko, Daria Fomina, Marcus Maurer, and Publica
Subjects: Urticaria, Immunoglobulin G, Immunology and Allergy, Humans, Chronic Urticaria, Immunoglobulin E, Iodide Peroxidase
Published: 2022

30. Adrenaline autoinjector is underprescribed in typical cold urticaria patients

Author: Mojca Bizjak, Mitja Košnik, Dejan Dinevski, Simon Francis Thomsen, Daria Fomina, Elena Borzova, Kanokvalai Kulthanan, Raisa Meshkova, Fernando Monteiro Aarestrup, Dalia Melina Ahsan, Mona Al‐Ahmad, Sabine Altrichter, Andrea Bauer, Maxi Brockstädt, Célia Costa, Semra Demir, Roberta Fachini Criado, Luis Felipe Ensina, Asli Gelincik, Ana Maria Giménez‐Arnau, Margarida Gonçalo, Maia Gotua, Jesper Grønlund Holm, Naoko Inomata, Alicja Kasperska‐Zajac, Maryam Khoshkhui, Aliya Klyucharova, Emek Kocatürk, Rongbiao Lu, Michael Makris, Natalya Maltseva, Maria Pasali, Marisa Paulino, David Pesqué, Jonny Peter, German Dario Ramón, Carla Ritchie, Solange Oliveira Rodrigues Valle, Michael Rudenko, Agnieszka Sikora, Nicola Wagner, Paraskevi Xepapadaki, Xiaoyang Xue, Zuotao Zhao, Dorothea Terhorst‐Molawi, and Marcus Maurer
Subjects: Epinephrine, Urticaria, adrenaline autoinjector, Cold-induced anaphylaxis, Immunology, cold urticaria, Cold Temperature, COLD-CE, cold-induced anaphylaxis, Cold urticaria, Immunology and Allergy, Humans, Adrenaline autoinjector, Anaphylaxis
Published: 2022

31. Milk-Specific IgE Reactivity Without Symptoms in Albumin-Sensitized Cat Allergic Patients

Author: Nataliya Ilina, Hans Grönlund, Elena S. Fedenko, Rudolf Valenta, Antonina Karsonova, Irina Evsegneeva, Dmitry Yu. Semenov, Natalya L. Bondarenko, Olga Elisyutina, Marianne van Hage, Mirela Curin, Musa Khaitov, Evgeny Beltyukov, Daria Fomina, Polina A. Glazkova, Alexander Karaulov, and Ksenja Riabova
Subjects: Pulmonary and Respiratory Medicine, Milk specific IgE, business.industry, Immunology, Albumin, Immunology and Allergy, Medicine, Reactivity (chemistry), business, Letter to the Editor
Published: 2021

32. Statement on Management of Children with Allergic Diseases During New Coronaviral Infection SARS-CoV-2 Pandemic (COVID-19 Infection)

Author: Daria Fomina, T. V. Kulichenko, Natalia M. Nenasheva, Elena Vishneva, Alexander Baranov, Natalia Ilina, Leyla Namazova-Baranova, and Khaitov Rakhim M
Subjects: Allergy, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), RM1-950, Asthma management, 03 medical and health sciences, 0302 clinical medicine, children, Pandemic, medicine, In patient, 030212 general & internal medicine, Intensive care medicine, Asthma, new coronaviral infection, allergic rhinitis, business.industry, Mortality rate, medicine.disease, allergy, sars-cov-2, 030228 respiratory system, covid-19, bronchial asthma, Therapeutics. Pharmacology, business
Abstract: The COVID-19 infection caused by the new coronavirus SARS-CoV-2 has become the real pandemic. Children account for 1–6% of all diagnosed COVID-19 cases. Generally, children have mild disease in comparison to adults, and their mortality rates are extremely low. Despite the fact that all the main efforts of the medical and political community are now focused on preventing the pandemic spread and organizing medical care for patients with moderate and severe COVID-19 course, we still have to remember to implement adequate help for patients with chronic diseases, especially for children with allergic diseases. The pandemic period coincided with natural weather period of dusting of causative plants, that led to annual escalation of both allergic rhinitis and asthma in patient group with specific sensitization to tree pollen. Leading experts of allergology (adapting to modern conditions) have created key guidelines on management of children with allergic diseases during the COVID-19 pandemic. These guidelines are based on the data and results from the Union of Pediatricians of Russia, Russian Association of Allergologists and Clinical Immunologists, European Academy of Allergy and Clinical Immunology (EAACI), European Respiratory Society (ERS), American Thoracic Society (ATS), Global Strategy for Asthma Management (GINA), Initiative on Allergic Rhinitis and its Impact on Asthma (ARIA/MACVIA).
Published: 2020

33. Toward personalization of asthma treatment according to trigger factors

Author: Luis Caraballo, Susanne Greber-Platzer, W. Pohl, Bulent Enis Sekerel, Valérie Siroux, Elena S. Fedenko, Natalia Ilina, Paolo Maria Matricardi, Harald Renz, Petra Pazderova, Zhanat Ispayeva, Elopy Sibanda, Kian Fan Chung, Nikolaos G. Papadopoulos, Hugo Van Bever, Marianne van Hage, Alexander Emelyanov, S. G. Makarova, Roxana S. Bumbacea, Carmen Panaitescu, Erika von Mutius, Faith H. A. Osier, Sebastian L. Johnston, Jin Lyu Sun, Gary W.K. Wong, R S Fassakhov, Ludmila P. Sizyakina, Kristina Borochova, Jiu-Yao Wang, Evgeny Beltyukov, Zhongshan Gao, Kari C. Nadeau, Antonina Karsonova, Marco Idzko, Snezhana Bychkovskaya, A.N. Pampura, Katarzyna Niespodziana, Peter Errhalt, Tatiana Baranovskaya, Dmitry Kudlay, M. Gotua, Natalia Astafyeva, Thomas Schlederer, Marek L. Kowalski, Rezeda Fayzullina, Musa Khaitov, Tetiana Umanets, Ksenja Riabova, Leyla Namazova-Baranova, Pedro Giavina-Bianchi, Ruby Pawankar, Mohamed-Ridha Barbouche, Zsolt Szépfalusi, Sergii Zaikov, Hae-Sim Park, Guillermo Horacio Docena, Irina Evsegneeva, Mihaela Zidarn, Michael Levin, Adnan Custovic, Jean Bousquet, Elena Kovzel, Paul M. O'Byrne, Daria Fomina, Oleksandr Nazarenko, Elena Borzova, Thomas Eiwegger, Olga Naumova, Gunilla Hedlin, Omer Kalayci, Rudolf Valenta, Vanitha Sampath, Angelika Berger, Margarita Vasileva, Alexander Karaulov, Graduate School, Medical Microbiology and Infection Prevention, AII - Inflammatory diseases, Salvy-Córdoba, Nathalie, Medizinische Universität Wien = Medical University of Vienna, Saratov State Medical University, Partenaires INRAE, Belarusian Medical Academy of Post-Graduate Education [Minsk] (BelMAPGE), Laboratoire d'immunologie clinique [Institut Pasteur de Tunis], Institut Pasteur de Tunis, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), South Ural State Medical University, Russian Medical Academy for Continuous Medical Education [Moscow], Pirogov Russian National Research Medical University, Sechenov First Moscow State Medical University, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Humboldt University Of Berlin, Berlin Institute of Health (BIH), University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Krasnoyarsk State Medical University (KrasSMU), Universidad de Cartagena [Cartagena de Indias], National Heart and Lung Institute [London] (NHLI), Imperial College London-Royal Brompton and Harefield NHS Foundation Trust, Universidad Nacional de la Plata [Argentine] (UNLP), The Hospital for sick children [Toronto] (SickKids), North-Western State Medical University [St Petersburg, Russia], Krems University Hospital, Kazan Federal University (KFU), Bashkir State University (BASHEDU), NRC Institute of immunology FMBA, Moscow Russian federation, Zhejiang Gongshang University [Hangzhou] (ZJSU), Universidade de São Paulo = University of São Paulo (USP), Tbilisi State University, Astrid Lindgren Children's Hospital, Karolinska University Hospital [Stockholm], Karolinska Institutet [Stockholm], Al-Farabi Kazakh National University [Almaty] (KazNU), Faculty of Medicine [Hacettepe University], Hacettepe University = Hacettepe Üniversitesi, Nazarbayev University [Kazakhstan], Medical University of Łódź (MUL), University of Cape Town, Dmitry Rogachev National Research Center of Pediatric Hematology, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Sean N. Parker Center for Allergy and Asthma Research [Stanford], Stanford Medicine, Stanford University-Stanford University, Pirogov Russian National Reasearch Medical University Moscow, National Academy of Medical Sciences of Ukraine, Shupyk National Medical Academy of Postgraduate Education [Kiev] (SNMAPE), Michael DeGroote School of Medicine [Hamilton, ON, Canada], Faculty of Health Sciences [Hamilton, ON, Canada], McMaster University [Hamilton, Ontario]-McMaster University [Hamilton, Ontario], KEMRI-Wellcome Trust Research Programme (KWTRP), Pius Branzeu Clinical Emergency Hospital (OncoGen), University of Manchester [Manchester], National and Kapodistrian University of Athens (NKUA), Ajou University, Nippon Medical School [Tokyo, Japon], Hietzing Hospital, Karl Landsteiner Institute for Dermatological Research, Landesklinikum St. Poelten, University of Giessen and Marburg Lung Center [Gießen, Germany] (UGMLC), German Center for Lung Research, University of Zimbawe [Harare] (UZ), University of Zimbawe, National University of Science and Technology [Bulawayo], Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) (IAB), Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Southern Federal University [Rostov-on-Don] (SFEDU), Peking Union Medical College Hospital [Beijing] (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, National University of Singapore (NUS), Center of Allergology and Clinical Immunology, Dr von Hauner Children's Hospital [Munich, Germany], Ludwig-Maximilians-Universität München (LMU), Helmholtz Centre Munich, German Centre for Lung Research, National Cheng Kung University Hospital [Tainan], The Chinese University of Hong Kong [Hong Kong], Respiratory and Allergic Diseases [Golnik, Slovenia], University Clinic of Respiratory and Allergic Diseases Golnik, University of Ljubljana, and Karl Landsteiner University of Health Sciences - Karl Landsteiner Privatuniversität für Gesundheitswissenschaften [Krems an der Donau, Austria]
Subjects: 0301 basic medicine, Allergy, MESH: Asthma, Rhinovirus, Asthma treatment, CHILDREN, EPITOPE, Disease, Microarray, medicine.disease_cause, sopenje, alergeni, Personalization, Atopy, 0302 clinical medicine, immune system diseases, astma, Immunology and Allergy, MESH: Animals, Precision Medicine, RISK, MESH: Rhinovirus, respiratorni znaki in simptomi, analiza mikromrež, Allergen, alergija in imunologija, SENSITIZATION, personalizirana medicina, Wheeze, rhinovirus, allergy and immunology, INFECTIONS, 1107 Immunology, wheeze, ATOPY, [SDV.IMM]Life Sciences [q-bio]/Immunology, medicine.symptom, Life Sciences & Biomedicine, Bioquímica, medicine.medical_specialty, MESH: Allergens, [SDV.IMM] Life Sciences [q-bio]/Immunology, precision medicine, Immunology, udc:616-097, MESH: Precision Medicine, 03 medical and health sciences, [SDV.MHEP.PED] Life Sciences [q-bio]/Human health and pathology/Pediatrics, rinovirus, medicine, Animals, Humans, allergens, IMMUNOTHERAPY, Intensive care medicine, Asthma, [SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics, MESH: Humans, Science & Technology, business.industry, Allergens, asthma, respiratory, medicine.disease, respiratory tract diseases, signs and symptoms, 030104 developmental biology, ANTIBODY, 030228 respiratory system, Ciencias Médicas, MESH: Biomarkers, microarray analysis, business, Biomarkers, RESPONSES
Abstract: Asthma is a severe and chronic disabling disease affecting more than 300 million people worldwide. Although in the past few drugs for the treatment of asthma were available, new treatment options are currently emerging, which appear to be highly effective in certain subgroups of patients. Accordingly, there is a need for biomarkers that allow selection of patients for refined and personalized treatment strategies. Recently, serological chip tests based on microarrayed allergen molecules and peptides derived from the most common rhinovirus strains have been developed, which may discriminate 2 of the most common forms of asthma, that is, allergen- and virus-triggered asthma. In this perspective, we argue that classification of patients with asthma according to these common trigger factors may open new possibilities for personalized management of asthma., La lista completa de autores que integran el documento puede consultarse en el archivo., Facultad de Ciencias Exactas
Published: 2020

34. EPIDEMIOLOGY OF PRIMARY IMMUNODEFICIENCIES IN THE RUSSIAN FEDERATION

Author: M.A. Grakhova, Omsk City Polyclinic No. , Omsk, Russia, I.V. Sazonova, L.Yu. Barycheva, N.B. Yudina, T.V. Shilova, Marina N. Guseva, L.I. Pyatkina, V.V. Lebedev, Irina Kondratenko, A.M. Milichkina, V.M. Shinkareva, Immunology named after Dmitry Rogachev, Moscow, Russia, N.A. Parfenova, E.G. Chernyshova, N.I. Ilyina, N.B. Kuzmenko, T.B. Pavlova, N.B. Migacheva, T.V. Samofalova, G.A. Davletbaeva, M.V. Gurkina, E.A. Goltsman, A.Yu. Shcherbina, N.V. Zinovieva, L.R. Kalmetieva, Daria Fomina, S.Yu. Starikova, O.P. Ukhanova, N.V. Shakhova, Irina A. Tuzankina, Microbiology, Saint Petersburg, Russia, Diagnostic Polyclinic No. , Volgograd, Russia, O.A. Rychkova, R.M. Khayrullina, S.B. Zimin, D.D. Prolygina, T.P. Alexandrova, L.S. Khachirova, E.V. Averina, T.V. Bukina, D.V. Mashkovskaya, Alexander Rumyantsev, Mother, S.S. Vakhlyarskaya, E.I. Kleshchenko, A.Yu. Kutlyantseva, Galina Novichkova, L.T. Kubanova, Z.I. Kruglaya Scientific, O.S. Selezneva, V.A. Alekseenko, F.I. Sibgatulina, I.A. Mirsayapova, K.A. Voronin, A.A. Totolyan, V.A. Kalinkina, S.N. Isakova, A.V. Gorenkova, O.M. Laba, M.M. Vasilyeva, Tatiana V. Latysheva, E.V. Efremenkov, Murmansk City Children's Polyclinic No. , Murmansk, Russia, K.P. Kuzmicheva, A.P. Prodeus, Consultative, A.A. Bologov, O.E. Pashchenko, I.V. Yarovaya, A.M. Kostinova, E.V. Vlasova, E.V. Timofeeva, A.V. Zhestkov, E.V. Troitskaya, A.L. Khoreva, Anna Mukhina, A.N. Pampura, A.S. Ermakova, G.V. Molokova, E.M. Kamaltynova, M.A. Bolkov, Z.V. Bambaeva, M.G. Ipatova, R.N. Suprun, E.V. Demikhova, T.V. Asekretova, D.N. Balashov, E.V. Volodina, E.A. Orlova, E.M. Gracheva, O.A. Shvets, Bryansk Clinical, G.I. Tsyvkina, Ekaterina A. Deordieva, Yu.A. Rodina, E.I. Sulima, I.V. Fisyun, S.N. Duryagina, V.G. Demikhov, I.V. Smoleva, E.A. Latysheva, Immunology, Vladivostok, Primorsky Krai, Russia, A.A. Moiseeva, E.V. Barmina, M.A. Filippova, and R.N. Kuznetsova
Subjects: medicine.medical_specialty, business.industry, Family medicine, Pediatrics, Perinatology and Child Health, Epidemiology, Medicine, Russian federation, business
Published: 2020

35. Features of diagnostics and clinical approaches to case management of patients with hereditary angioedema without C1 esterase inhibitor deficiency. Analysis of the clinical case

Author: Elena N Bobrikova, Daria Fomina, and Sofia A Serdotetskova
Subjects: medicine.medical_specialty, business.industry, Hereditary angioedema, Medicine, Clinical case, General Medicine, business, medicine.disease, Case management, Dermatology, C1 esterase inhibitor deficiency
Abstract: This article describes the clinical, biochemical and genetic features of hereditary angioedema (HAE) with normal level and functional activity of C1 esterase inhibitor. The discussion includes pathogenesis, diagnostics and case management of patients with hereditary angioedema without C1 esterase inhibitor deficiency. The materials of few scientific sources about patients with HAE without C1 esterase inhibitor deficiency in stages and our own clinical case (the female patient of fertile age with a confirmed mutation associated with factor XII (Hageman) deficiency) was given. The article describes the current state of the issue of the algorithm of primary diagnostics and differential diagnostics of HAE without C1 esterase inhibitor deficiency based on international and Russian data. It has been suggested that the new understanding of pathogenesis and treatment of patients with HAE without C1 esterase inhibitor deficiency is encouraging and becoming accessible to the medical society.
Published: 2020

36. Risk factors for systemic reactions in typical cold urticaria: Results from the COLD-CE study

Author: Emek Kocatürk, Ana Giménez-Arnau, Roberta Fachini Jardim Criado, David Pesqué, Maria Pasali, Solange Oliveira Rodrigues Valle, Simon Francis Thomsen, Mitja Košnik, Daria Fomina, Aliya Klyucharova, Célia Costa, Dejan Dinevski, Rongbiao Lu, Luis Felipe Ensina, Paraskevi Xepapadaki, Michael Makris, Sabine Altrichter, Maryam Khoshkhui, Naoko Inomata, Dalia Melina Ahsan, Elena Borzova, Maxi Brockstädt, Andrea Bauer, German D. Ramon, Xiaoyang Xue, Eduardo Magalhães de Souza Lima, Zuotao Zhao, Kanokvalai Kulthanan, Dorothea Terhorst-Molawi, Jesper Grønlund Holm, Mona Al-Ahmad, Jovan Miljković, Marisa Paulino, Margarida Gonçalo, Semra Demir, Alicja Kasperska-Zajac, Agnieszka Sikora, Jonny Peter, M. Gotua, Natalya Maltseva, Michael Rudenko, Marcus Maurer, Mojca Bizjak, Carla Ritchie, Aslı Gelincik, Raisa Meshkova, Nicola Wagner, Publica, Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Bizjak, Mojca, Kosnik, Mitja, Dinevski, Dejan, Thomsen, Simon Francis, Fomina, Daria, Borzova, Elena, Kulthanan, Kanokvalai, Meshkova, Raisa, Ahsan, Dalia Melina, Al-Ahmad, Mona, Altrichter, Sabine, Bauer, Andrea, Brockstadt, Maxi, Costa, Celia, Demir, Semra, Criado, Roberta Fachini, Ensina, Luis Felipe, Gelincik, Aslı, Gimenez-Arnau, Ana Maria, Goncalo, Margarida, Gotua, Maia, Holm, Jesper Gronlund, Inomata, Naoko, Kasperska-Zajac, Alicja, Khoshkhui, Maryam, Klyucharova, Aliya, Lu, Rongbiao, Makris, Michael, Maltseva, Natalya, Miljkovic, Jovan, Pasali, Maria, Paulino, Marisa, Pesque, David, Peter, Jonny, Ramon, German Dario, Ritchie, Carla, Valle, Solange Oliveira Rodrigues, Rudenko, Michael, Sikora, Agnieszka, Lima, Eduardo M. Souza, Wagner, Nicola, Xepapadaki, Paraskevi, Xue, Xiaoyang, Zhao, Zuotao, Terhorst-Molawi, Dorothea, Maurer, Marcus, and School of Medicine
Subjects: medicine.medical_specialty, Urticaria, adrenaline autoinjector, Immunology, systemic reactions, Cold urticaria, Autoinjector, Risk Factors, medicine, risk factors, Immunology and Allergy, Animals, Humans, Chronic Urticaria, Angioedema, Adrenaline autoinjector, COLD-CE, Risk factors, Systemic reactions, Allergy, business.industry, Pruritus, Cold air, Insect Bites and Stings, medicine.disease, Dermatology, Hymenoptera, cold urticaria, Cold Temperature, Sting, Systemic reaction, Cross-Sectional Studies, Concomitant, medicine.symptom, business, Anaphylaxis, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
Abstract: Background: cold urticaria (ColdU), that is, the occurrence of wheals or angioedema in response to cold exposure, is classified into typical and atypical forms. The diagnosis of typical ColdU relies on whealing in response to local cold stimulation testing (CST). It can also manifest with cold-induced anaphylaxis (ColdA). We aimed to determine risk factors for ColdA in typical ColdU. Methods: an international, cross-sectional study COLD-CE was carried out at 32 urticaria centers of reference and excellence (UCAREs). Detailed history was taken and CST with an ice cube and/or TempTest(R) performed. ColdA was defined as an acute cold-induced involvement of the skin and/or visible mucosal tissue and at least one of: cardiovascular manifestations, difficulty breathing, or gastrointestinal symptoms. Results: of 551 ColdU patients, 75% (n = 412) had a positive CST and ColdA occurred in 37% (n = 151) of the latter. Cold-induced generalized wheals, angioedema, acral swelling, oropharyngeal/laryngeal symptoms, and itch of earlobes were identified as signs/symptoms of severe disease. ColdA was most commonly provoked by complete cold water immersion and ColdA caused by cold air was more common in countries with a warmer climate. Ten percent (n = 40) of typical ColdU patients had a concomitant chronic spontaneous urticaria (CSU). They had a lower frequency of ColdA than those without CSU (4% vs. 39%, p = .003). We identified the following risk factors for cardiovascular manifestations: previous systemic reaction to a Hymenoptera sting, angioedema, oropharyngeal/laryngeal symptoms, and itchy earlobes. Conclusion: coldA is common in typical ColdU. High-risk patients require education about their condition and how to use an adrenaline autoinjector., GA(2)LEN UCARE Network
Published: 2021

37. Low and high IgE is linked to improvement and worsening of chronic urticaria during pregnancy, respectively

Author: Emek Kocatürk, Simon Francis Thomsen, Mona Al-Ahmad, Ana Giménez Arnau, Niall Conlon, Ekin Şavk, Roberta Criado, Inna Danilycheva, Daria Fomina, Maryam Khoshkhui, Aslı Gelincik, Ece Nur Degirmentepe, semra demir, Luis Ensina, Alicja Kasperska-Zając, Michael Rudenko, Andrea Bauer, Iris Medina, and Marcus Maurer
Published: 2021

38. Different paterns of autoAbs in asthma-COPD overlap cogort

Author: Galina Osipova, Valentina Gervazieva, Tatiana Ospelnikova, Daria Fomina, and Anna Konishcheva
Subjects: medicine.medical_specialty, business.industry, Internal medicine, Medicine, Asthma copd overlap, business
Published: 2021

39. Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial

Author: Roberto, Caricchio, Antonio, Abbate, Ivan, Gordeev, Jamie, Meng, Priscilla Y, Hsue, Tuhina, Neogi, Roberto, Arduino, Daria, Fomina, Roman, Bogdanov, Tatiana, Stepanenko, Pilar, Ruiz-Seco, Andrés, Gónzalez-García, Yu, Chen, Yuhan, Li, Sarah, Whelan, Stephanie, Noviello, and George, Wohlford
Subjects: Male, medicine.medical_specialty, Interleukin-1beta, Kaplan-Meier Estimate, Placebo, Antibodies, Monoclonal, Humanized, law.invention, Fibrin Fibrinogen Degradation Products, Randomized controlled trial, Double-Blind Method, law, Internal medicine, Clinical endpoint, Medicine, Humans, Adverse effect, Survival rate, Aged, Original Investigation, business.industry, COVID-19, General Medicine, Odds ratio, Middle Aged, Combined Modality Therapy, Respiration, Artificial, COVID-19 Drug Treatment, Clinical trial, Hospitalization, Survival Rate, Canakinumab, C-Reactive Protein, Treatment Outcome, Ferritins, Female, business, medicine.drug
Abstract: IMPORTANCE: Effective treatments for patients with severe COVID-19 are needed. OBJECTIVE: To evaluate the efficacy of canakinumab, an anti–interleukin-1β antibody, in patients hospitalized with severe COVID-19. DESIGN, SETTING, AND PARTICIPANTS: This randomized, double-blind, placebo-controlled phase 3 trial was conducted at 39 hospitals in Europe and the United States. A total of 454 hospitalized patients with COVID-19 pneumonia, hypoxia (not requiring invasive mechanical ventilation [IMV]), and systemic hyperinflammation defined by increased blood concentrations of C-reactive protein or ferritin were enrolled between April 30 and August 17, 2020, with the last assessment of the primary end point on September 22, 2020. INTERVENTION: Patients were randomly assigned 1:1 to receive a single intravenous infusion of canakinumab (450 mg for body weight of 40-80 kg; n = 227) or placebo (n = 227). MAIN OUTCOMES AND MEASURES: The primary outcome was survival without IMV from day 3 to day 29. Secondary outcomes were COVID-19–related mortality, measurements of biomarkers of systemic hyperinflammation, and safety evaluations. RESULTS: Among 454 patients who were randomized (median age, 59 years; 187 women [41.2%]), 417 (91.9%) completed day 29 of the trial. Between days 3 and 29, 198 of 223 patients (88.8%) survived without requiring IMV in the canakinumab group and 191 of 223 (85.7%) in the placebo group, with a rate difference of 3.1% (95% CI, −3.1% to 9.3%) and an odds ratio of 1.39 (95% CI, 0.76 to 2.54; P = .29). COVID-19–related mortality occurred in 11 of 223 patients (4.9%) in the canakinumab group vs 16 of 222 (7.2%) in the placebo group, with a rate difference of −2.3% (95% CI, −6.7% to 2.2%) and an odds ratio of 0.67 (95% CI, 0.30 to 1.50). Serious adverse events were observed in 36 of 225 patients (16%) treated with canakinumab vs 46 of 223 (20.6%) who received placebo. CONCLUSIONS AND RELEVANCE: Among patients hospitalized with severe COVID-19, treatment with canakinumab, compared with placebo, did not significantly increase the likelihood of survival without IMV at day 29. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04362813
Published: 2021

40. How are patients with chronic urticaria interested in using information and communication technologies to guide their healthcare? A UCARE study

Author: Emek Kocatürk, Roberta F. Criado, Carla Ritchie, Mohamed Abuzakouk, Simon Francis Thomsen, Annia Cherrez, Jose Ignacio Larco, Carole Guillet, Agnieszka Sikora, Zuotao Zhao, Deepa Grandon, Marcus Maurer, Elena Kovalkova, Miguel Felix, Ana Giménez-Arnau, Ivan Cherrez-Ojeda, Daria Fomina, Karsten Weller, Alicja Kasperska-Zajac, Eduardo Magalhães de Souza Lima, Emanuel Vanegas, Sofia Cherrez, Paraskevi Xepapadaki, Michael Makris, Edgar Emilio Matos Benavides, Kiran Godse, Sahar Rastgoo, Rasmus Robin Maurer, Martijn B. A. van Doorn, Luis Felipe Ensina, Valeria L. Mata, Maryam Khoshkhui, Andrea Bauer, Solange Oliveira Rodrigues Valle, Nimmagadda Dheeraj Rao, German D. Ramon, Markus Magerl, Dermatology, Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Cherrez-Ojeda, I., Vanegas, E., Cherrez, A., Felix, M., Weller, K., Magerl, M., Maurer, R. R., Mata, V. L., Kasperska-Zajac, A., Sikora, A., Fomina, D., Kovalkova, E., Godse, K., Rao, N. D., Khoshkhui, M., Rastgoo, S., Criado, R. F., Abuzakouk, M., Grandon, D., Van Doorn, M. B. A., Oliveira Rodrigues Valle, S., De Souza Lima, E. M., Thomsen, S. F., Ramón, G. D., Matos Benavides, E. E., Bauer, A., Giménez-Arnau, A. M., Guillet, C., Larco, J. I., Zhao, Z.- T., Makris, M., Ritchie, C., Xepapadaki, P., Ensina, L. F., Cherrez, S., Maurer, M., Koç University Hospital, and School of Medicine
Subjects: Pulmonary and Respiratory Medicine, Higher education, media_common.quotation_subject, Immunology, WhatsApp, Information and communication technologies, NEEDS, Article, 03 medical and health sciences, 0302 clinical medicine, PHYSICIANS, Excellence, ComputerApplications_MISCELLANEOUS, Health care, parasitic diseases, Immunology and Allergy, Medicine, 030223 otorhinolaryngology, Chronic urticaria, media_common, Medical education, Internet, Allergy, E-mail, business.industry, RC581-607, 030228 respiratory system, Information and Communications Technology, e-mail, The Internet, ICTS, Rural area, Immunologic diseases. Allergy, business, BURDEN
Abstract: Background: patients with chronic urticaria (CU) are increasingly using information and communication technologies (ICTs) to manage their health. What CU patients expect from ICTs and which ICTs they prefer remains unknown. We assessed why CU patients use ICTs, which ones they prefer, and what drives their expectations and choices. Methods: in this cross-sectional study, 1841 patients across 17 countries were recruited at UCAREs (Urticaria Centers of Reference and Excellence). Patients with CU who were >12 years old completed a 23-item questionnaire. Results: most patients were interested in receiving disease information (87.3%), asking physicians about CU (84.1%), and communicating with other patients through ICTs (65.6%). For receiving disease information, patients preferred one-to-one and one-to-many ICTs, especially web browsers. One-to-one ICTs were also the ICTs of choice for asking physicians about urticaria and for communicating with other patients, and e-mail and WhatsApp were the preferred ICTs, respectively. Many-to-many ICTs such as Facebook, Instagram, LinkedIn, and Twitter were least preferred for all 3 purposes. Living in rural areas and higher education were linked to higher odds of being interested in receiving disease information, asking physicians, and communicating with patients through ICTs. Conclusions: most patients and especially patients with higher education who live in rural areas are interested in using ICTs for their healthcare, but prefer different ICTs for different purposes, ie, web browsers for obtaining information, e-mail for asking physicians, and WhatsApp for communicating with other patients. Our findings may help to improve ICTs for CU., GA2LEN Network of Urticaria Centers of Reference and Excellence (UCARE); World Allergy Organization (WAO)
Published: 2021

41. Effects of pregnancy on chronic urticaria: Results of the PREG-CU UCARE study

Author: Ana Giménez-Arnau, Can Ateş, Michael Rudenko, Ece Nur Degirmentepe, Maryam Khoshkhui, Alicja Kasperska-Zajac, Emek Kocatürk, Roberta Fachini Jardim Criado, I V Danilycheva, Aslı Gelincik, Semra Demir, Luis Felipe Ensina, A. Marsland, Karoline Krause, Özlem Su Küçük, Ekin Şavk, Laurence Bouillet, Niall Conlon, Andrea Bauer, Simon Francis Thomsen, Petra Staubach, Kiran Godse, Mona Al-Ahmad, Iris V Medina, Marcus Maurer, Solange Oliveira Rodrigues Valle, Daria Fomina, Zuotao Zhao, Tıp Fakültesi, and KÜÇÜK, Özlem Su
Subjects: 0301 basic medicine, Allergy, medicine.medical_specialty, Urticaria, Immunology, Breastfeeding, Disease activity, 03 medical and health sciences, 0302 clinical medicine, Pregnancy, Surveys and Questionnaires, Results of the PREG-CU UCARE study-, ALLERGY, cilt.76, sa.10, ss.3133-3144, 2021 [Kocaturk E., Al-Ahmad M., Krause K., Gimenez-Arnau A. M. , Thomsen S. F. , Conlon N., Marsland A., Savk E., Criado R. F. , Danilycheva I., et al., -Effects of pregnancy on chronic urticaria], Immunology and Allergy, Medicine, Humans, Chronic Urticaria, Angioedema, Disease Activity, Gonadal Steroid Hormones, Chronic urticaria, business.industry, Obstetrics, Previous pregnancy, food and beverages, medicine.disease, Hormones, 030104 developmental biology, 030228 respiratory system, Multicenter study, Chronic Disease, Female, medicine.symptom, business
Abstract: *Ateş, Can ( Aksaray, Yazar ), SciVal Topics Funding details Abstract Background: Chronic urticaria (CU) predominantly affects women, and sex hormones can modulate disease activity in female CU patients. As of now, the impact of pregnancy on CU is largely unknown. Aim: To analyze the course and features of CU during and after pregnancy. Patients and methods: PREG-CU is an international, multicenter study of the Urticaria Centers of Reference and Excellence (UCARE) network. Data were collected via a 47-item questionnaire completed by CU patients, who became pregnant within the last 3 years. Results: A total of 288 pregnancies of 288 CU patients from 13 countries were analyzed (mean age at pregnancy: 32.1 ± 6.1 years, duration of CU: 84.9 ± 74.5 months; CSU 66.9%, CSU + CIndU 20.3%, CIndU 12.8%).During pregnancy, 51.1% of patients rated their CU as improved, 28.9% as worse, and 20.0% as unchanged.CU exacerbations most commonly occurred exclusively during the third trimester (in 34 of 124 patients; 27.6%) or the first (28 of 124; 22.8%). The risk factors for worsening of CU during pregnancy were having mild disease and no angioedema before pregnancy, not taking treatment before pregnancy, CIndU, CU worsening during a previous pregnancy, treatment during pregnancy, and stress as a driver of exacerbations. After giving birth, urticaria disease activity remained unchanged in 43.8% of CU patients, whereas 37.4% and 18.1% experienced worsening and improvement, respectively. Conclusions: These results demonstrate the complex impact of pregnancy on the course of CU and help to better counsel patients who want to become pregnant and to manage CU during pregnancy.
Published: 2021

42. Highly sensitive ELISA‐based assay for quantification of allergen‐specific IgE antibody levels

Author: Rudolf Valenta, Marianne van Hage, Alexander Karaulov, Antonina Karsonova, Hans Grönlund, Ksenja Riabova, Olga Elisyutina, Verena Niederberger, Evgeniy Beltiukov, Yury Zhernov, Julia Eckl-Dorna, Raffaela Campana, Mirela Curin, Elena S. Fedenko, Musa Khaitov, Sergio Villazala-Merino, Thomas Perkmann, Renate Fröschl, and Daria Fomina
Subjects: Allergy, biology, business.industry, Immunology, Immunologic Tests, Enzyme-Linked Immunosorbent Assay, Antibody level, Allergens, Immunoglobulin E, medicine.disease, medicine.disease_cause, Highly sensitive, Allergen, Antibody Specificity, biology.protein, medicine, Humans, Immunology and Allergy, Letters to the Editor, business, Letter to the Editor, Allergen specific IgE
Published: 2020

43. Autoimmune Chronic Spontaneous Urticaria Detection with IgG Anti-TPO and Total IgE

Author: Elena Kovalkova, Daria Fomina, Marcus Maurer, Karoline Krause, Merle Sauer, Anton A. Chernov, Pavel Kolkhir, Andrey E. Shulzhenko, and I V Danilycheva
Subjects: Urticaria, Basopenia, Basophil, Immunologic Tests, Immunoglobulin E, Thyroid peroxidase, Immunology and Allergy, Medicine, Eosinopenia, Humans, Chronic Urticaria, Autoantibodies, Angioedema, biology, business.industry, medicine.disease, Anti-thyroid autoantibodies, Basophil activation, medicine.anatomical_structure, Immunoglobulin G, Immunology, Chronic Disease, biology.protein, Female, medicine.symptom, business
Abstract: Autoimmune chronic spontaneous urticaria (aiCSU) comes with high disease activity and poor response to treatment. Recently, elevated levels of IgG anti-thyroid peroxidase (aTPO) and low levels of total IgE were reported to be common in aiCSU.To investigate how high aTPO and low IgE individually and combined are linked to features of aiCSU, including treatment responses.We analyzed records of patients with CSU from 2 independent cohorts (n = 1120) for demographic, clinical, and laboratory parameters and treatment responses. Total IgE and aTPO were measured, and 4 markers of aiCSU were analyzed: autologous serum skin test, basophil activation test (BAT), and blood eosinophil and basophil counts. Cutoff values were greater than or equal to 34 kU/L (high aTPO) and less than 40 IU/mL (low total IgE).One of 10 patients with CSU had both high aTPO and low IgE (aTPO↑IgE↓, 11%, n = 123). aTPO↑IgE↓ was linked to higher age at CSU onset, being female, angioedema, and shorter CSU duration. aTPO↑IgE↓ was associated with markers of aiCSU, that is, BAT and autologous serum skin test positivity, basopenia, and eosinopenia (P.01 for all). Almost half the patients with aTPO↑IgE↓ (44%, 19 of 43) had a positive BAT result, the best single marker for aiCSU, versus 12% (43 of 344) of patients without aTPO↑IgE↓ (P.001). Relative risk of showing BAT positivity for a patient with aTPO↑IgE↓ is 3.636 (95% CI, 2.382-5.551). Patients with aTPO↑IgE↓ showed low response rates to antihistamine treatment as compared with patients without aTPO↑IgE↓ (30% vs 47%; P = .01).Our findings suggest that aTPO↑IgE↓ is a useful diagnostic marker for aiCSU in everyday clinical practice.
Published: 2021

44. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

Author: François-Xavier Lescure, Hitoshi Honda, Robert A Fowler, Jennifer Sloane Lazar, Genming Shi, Peter Wung, Naimish Patel, Owen Hagino, Ignacio J. Bazzalo, Marcelo M. Casas, Sebastián A. Nuñez, Yael Pere, Carlos M. Ibarrola, Marco A. Solis Aramayo, Maria C. Cuesta, Andrea E. Duarte, Pablo M. Gutierrez Fernandez, Maria A. Iannantuono, Erica A. Miyazaki, Javier P. Silvio, Dario G. Scublinsky, Alessandra Bales, Daniela Catarino, Elie Fiss, Sara Mohrbacher, Victor Sato, Antonio Baylao, Adilson Cavalcante, Francini Correa, Celso A. de Andrade, Juvencio Furtado, Nelson Ribeiro Filho, Valéria Telles, Leopoldo T. Trevelin, Ricardo Vipich, Rodrigo Boldo, Paula Borges, Suzana Lobo, Graziela Luckemeyer, Luana Machado, Maysa B. Alves, Ana C. Iglessias, Marianna M. Lago, Daniel W. Santos, Hugo Chapdelaine, Emilia L. Falcone, Rahima Jamal, Me-Linh Luong, Madeleine Durand, Stephane Doucet, François-Martin Carrier, Bryan A. Coburn, Lorenzo Del Sorbo, Sharon L. Walmsley, Sara Belga, Luke Y. Chen, Allison D. Mah, Theodore Steiner, Alissa J. Wright, J. Hajek, Neill Adhikari, Robert A. Fowler, Nick Daneman, Kosar A. Khwaja, Jason Shahin, Carolina Gonzalez, Rafael Silva, Marcelo Lindh, Gabriel Maluenda, Patricia Fernandez, Maite Oyonarte, Martin Lasso, Alexandre Boyer, Didier Bronnimann, Hoang-Nam Bui, Charles Cazanave, Helene Chaussade, Arnaud Desclaux, Mailys Ducours, Alexandre Duvignaud, Denis Malvy, Lisa Martin, Didier Neau, Duc Nguyen, Thierry Pistone, Gaetane Soubrane-Wirth, Julie Leitao, Clotilde Allavena, Charlotte Biron, Sabelline Bouchez, Benjamin Gaborit, Antoine Gregoire, Paul Le Turnier, Anne-Sophie Lecompte, Raphael Lecomte, Maeva Lefebvre, Francois Raffi, David Boutoille, Pascale H. Morineau, Romain Guéry, Emmanuel Chatelus, Nathalie Dumoussaud, Renaud Felten, Florina Luca, Bernard Goichot, Francis Schneider, Marie-Caroline Taquet, Matthieu Groh, Mathilde Roumier, Mathilde Neuville, Antoine Bachelard, Valentina Isernia, F-Xavier Lescure, Bao-Chau Phung, Anne Rachline, Aurelie Sautereau, Dorothee Vallois, Yves Bleher, Delphine Boucher, Clémentine Coudon, Jean Esnault, Thomas Guimard, Sophie Leautez-Nainville, Dominique Merrien, Marine Morrier, Pauline Motte-Vincent, Romain Gabeff, Hélène Leclerc, Céline Cozic, Romain Decours, Ronan Février, Gwenhael Colin, Sophie Abgrall, Dorothee Vignes, Raluca Sterpu, Mira Kuellmar, Melanie Meersch-Dini, Raphael Weiss, Alexander Zarbock, Christiane Antony, Marc Berger, Thorsten Brenner, Christian Taube, Frank Herbstreit, Sebastian Dolff, Margarethe Konik, Karsten Schmidt, Markus Zettler, Oliver Witzke, Boris Boell, Jorge Garcia Borrega, Philipp Koehler, Thomas Zander, Fabian Dusse, Othman Al-Sawaf, Philipp Köhler, Dennis Eichenauer, Matthias Kochanek, Alexander Shimabukuro-Vornhagen, Sibylle Mellinghoff, Annika Claßen, Jan-Michel Heger, Charlotte Meyer-Schwickerath, Paul Liedgens, Katrin Heindel, Ana Belkin, Asaf Biber, Mayan Gilboa, Itzchak Levy, Vladislav Litachevsky, Galia Rahav, Anat Finesod Wiedner, Tal Zilberman-Daniels, Yonatan Oster, Jacob Strahilevitz, Sigal Sviri, Elena M. Baldissera, Corrado Campochiaro, Giulio Cavalli, Lorenzo Dagna, Giacomo De Luca, Emanuel Della Torre, Alessandro Tomelleri, Davide Bernasconi De Luca, Amedeo F. Capetti, Massimo Coen, Maria V. Cossu, Massimo Galli, Andrea Giacomelli, Guido A. Gubertini, Stefano Rusconi, Giulia J. Burastero, Margherita Digaetano, Giovanni Guaraldi, Marianna Meschiari, Cristina Mussini, Cinzia Puzzolante, Sara Volpi, Marina Aiello, Alarico Ariani, Alfredo A. Chetta, Annalisa Frizzelli, Andrea Ticinesi, Domenico Tuttolomondo, Stefano Aliberti, Francesco B. Blasi, Marta F. Di Pasquale, Sofia Misuraca, Tommaso Pilocane, Edoardo Simonetta, Alessio M. Aghelmo, Claudio Angelini, Enrico Brunetta, Giorgio W. Canonica, Michele Ciccarelli, Sara Dal Farra, Maria De Santis, Sebastian Ferri, Marco Folci, Giacomo M. Guidelli, Enrico M. Heffler, Ferdinando Loiacono, Giacomo Malipiero, Giovanni Paoletti, Rosa Pedale, Francesca A. Puggioni, Francesca Racca, Aurora Zumbo, Morihiko Satou, Tatyana Lisun, Denis Protsenko, Nikolay Rubtsov, Irina Beloglazova, Daria Fomina, Mariana Lysenko, Sofia Serdotetskova, Vitali Firstov, Ivan Gordeev, Ilia Kokorin, Ksenia Komissarova, Nina Lapochkina, Elena Luchinkina, Valentin Malimon, Sevinch Mamedguseyinova, Ksenia Polubatonova, Natalia Suvorova, Jose Arribas, Alberto M. Borobia Perez, Fernando de la Calle Prieto, Juan Carlos Figueira, Rocio Motejano Sanchez, Marta Mora-Rillo, Concepcion Prados Sanchez, Javier Queiruga Parada, Francisco Fernandez Arnalich, Maria Guerro Barrientos, Alejandro Bendala Estrada, Aranzazu Caballero Marcos, Maria E. Garcia Leoni, Rita García-Martínez, Ana María Collado, Patricia Munoz Garcia, Ana Torres do Rego, María V. Villalba García, Almudena Burrillo, Maricela Valerio Minero, Paloma Gijon Vidaurreta, Sonsoles Infante Herrero, Elena Velilla, Marina Machado, Maria Olmedo, Blanca Pinilla, Benito Almirante Gragera, Maria de la Esperanza Cañas Ruano, Sofia Contreras Medina, Alejandro Cortés Herrera, Vicenç Falcó Ferrer, Ricard Ferrer Roca, Xavier Nuvials Casals, Esteve Ribera Pascuet, Paula Suanzes Diez, Pedro Rebollo Castro, Felipe Garcia Alcaide, Alejandro Soriano, Aina Oliver Caldes, Ana González Cordón, Celia Cardozo, Lorena De la Mora Cañizo, Romina Pena López, Sandra Chamorro, Clara Crespillo-Andujar, Rosa Escudero Sanchez, Jesús Fortún-Abete, Begoña Monge-Maillo, Ana Moreno Zamora, Francesca Norman, Matilde Sanchez Conde, Sergio Serrano Villar, Pilar Vizcarra, Lescure, F. -X., Honda, H., Fowler, R. A., Lazar, J. S., Shi, G., Wung, P., Patel, N., Hagino, O., Bazzalo, I. J., Casas, M. M., Nunez, S. A., Pere, Y., Ibarrola, C. M., Solis Aramayo, M. A., Cuesta, M. C., Duarte, A. E., Gutierrez Fernandez, P. M., Iannantuono, M. A., Miyazaki, E. A., Silvio, J. P., Scublinsky, D. G., Bales, A., Catarino, D., Fiss, E., Mohrbacher, S., Sato, V., Baylao, A., Cavalcante, A., Correa, F., de Andrade, C. A., Furtado, J., Ribeiro Filho, N., Telles, V., Trevelin, L. T., Vipich, R., Boldo, R., Borges, P., Lobo, S., Luckemeyer, G., Machado, L., Alves, M. B., Iglessias, A. C., Lago, M. M., Santos, D. W., Chapdelaine, H., Falcone, E. L., Jamal, R., Luong, M. -L., Durand, M., Doucet, S., Carrier, F. -M., Coburn, B. A., Del Sorbo, L., Walmsley, S. L., Belga, S., Chen, L. Y., Mah, A. D., Steiner, T., Wright, A. J., Hajek, J., Adhikari, N., Daneman, N., Khwaja, K. A., Shahin, J., Gonzalez, C., Silva, R., Lindh, M., Maluenda, G., Fernandez, P., Oyonarte, M., Lasso, M., Boyer, A., Bronnimann, D., Bui, H. -N., Cazanave, C., Chaussade, H., Desclaux, A., Ducours, M., Duvignaud, A., Malvy, D., Martin, L., Neau, D., Nguyen, D., Pistone, T., Soubrane-Wirth, G., Leitao, J., Allavena, C., Biron, C., Bouchez, S., Gaborit, B., Gregoire, A., Le Turnier, P., Lecompte, A. -S., Lecomte, R., Lefebvre, M., Raffi, F., Boutoille, D., Morineau, P. H., Guery, R., Chatelus, E., Dumoussaud, N., Felten, R., Luca, F., Goichot, B., Schneider, F., Taquet, M. -C., Groh, M., Roumier, M., Neuville, M., Bachelard, A., Isernia, V., Phung, B. -C., Rachline, A., Sautereau, A., Vallois, D., Bleher, Y., Boucher, D., Coudon, C., Esnault, J., Guimard, T., Leautez-Nainville, S., Merrien, D., Morrier, M., Motte-Vincent, P., Gabeff, R., Leclerc, H., Cozic, C., Decours, R., Fevrier, R., Colin, G., Abgrall, S., Vignes, D., Sterpu, R., Kuellmar, M., Meersch-Dini, M., Weiss, R., Zarbock, A., Antony, C., Berger, M., Brenner, T., Taube, C., Herbstreit, F., Dolff, S., Konik, M., Schmidt, K., Zettler, M., Witzke, O., Boell, B., Garcia Borrega, J., Koehler, P., Zander, T., Dusse, F., Al-Sawaf, O., Kohler, P., Eichenauer, D., Kochanek, M., Shimabukuro-Vornhagen, A., Mellinghoff, S., Classen, A., Heger, J. -M., Meyer-Schwickerath, C., Liedgens, P., Heindel, K., Belkin, A., Biber, A., Gilboa, M., Levy, I., Litachevsky, V., Rahav, G., Finesod Wiedner, A., Zilberman-Daniels, T., Oster, Y., Strahilevitz, J., Sviri, S., Baldissera, E. M., Campochiaro, C., Cavalli, G., Dagna, L., De Luca, Giacomo., Della Torre, E., Tomelleri, A., Bernasconi De Luca, D., Capetti, A. F., Coen, M., Cossu, M. V., Galli, M., Giacomelli, A., Gubertini, G. A., Rusconi, S., Burastero, G. J., Digaetano, M., Guaraldi, G., Meschiari, M., Mussini, C., Puzzolante, C., Volpi, S., Aiello, M., Ariani, A., Chetta, A. A., Frizzelli, A., Ticinesi, A., Tuttolomondo, D., Aliberti, S., Blasi, F. B., Di Pasquale, M. F., Misuraca, S., Pilocane, T., Simonetta, E., Aghelmo, A. M., Angelini, C., Brunetta, E., Canonica, G. W., Ciccarelli, M., Dal Farra, S., De Santis, M., Ferri, S., Folci, M., Guidelli, G. M., Heffler, E. M., Loiacono, F., Malipiero, G., Paoletti, G., Pedale, R., Puggioni, F. A., Racca, F., Zumbo, A., Satou, M., Lisun, T., Protsenko, D., Rubtsov, N., Beloglazova, I., Fomina, D., Lysenko, M., Serdotetskova, S., Firstov, V., Gordeev, I., Kokorin, I., Komissarova, K., Lapochkina, N., Luchinkina, E., Malimon, V., Mamedguseyinova, S., Polubatonova, K., Suvorova, N., Arribas, J., Borobia Perez, A. M., de la Calle Prieto, F., Figueira, J. C., Motejano Sanchez, R., Mora-Rillo, M., Prados Sanchez, C., Queiruga Parada, J., Fernandez Arnalich, F., Guerro Barrientos, M., Bendala Estrada, A., Caballero Marcos, A., Garcia Leoni, M. E., Garcia-Martinez, R., Collado, A. M., Munoz Garcia, P., Torres do Rego, A., Villalba Garcia, M. V., Burrillo, A., Valerio Minero, M., Gijon Vidaurreta, P., Infante Herrero, S., Velilla, E., Machado, M., Olmedo, M., Pinilla, B., Almirante Gragera, B., Canas Ruano, M. D. L. E., Contreras Medina, S., Cortes Herrera, A., Falco Ferrer, V., Ferrer Roca, R., Nuvials Casals, X., Ribera Pascuet, E., Suanzes Diez, P., Rebollo Castro, P., Garcia Alcaide, F., Soriano, A., Oliver Caldes, A., Gonzalez Cordon, A., Cardozo, C., De la Mora Canizo, L., Pena Lopez, R., Chamorro, S., Crespillo-Andujar, C., Escudero Sanchez, R., Fortun-Abete, J., Monge-Maillo, B., Moreno Zamora, A., Norman, F., Sanchez Conde, M., Serrano Villar, S., and Vizcarra, P.
Subjects: Male, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Critical Care, International Cooperation, Population, Antibodies, Monoclonal, Humanized, Placebo, Severity of Illness Index, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Intensive care, Severity of illness, medicine, Clinical endpoint, Humans, Immunologic Factors, 030212 general & internal medicine, Mortality, education, Respiratory Distress Syndrome, education.field_of_study, Dose-Response Relationship, Drug, SARS-CoV-2, business.industry, Hazard ratio, COVID-19, Articles, Middle Aged, Receptors, Interleukin-6, Sarilumab, Treatment Outcome, 030228 respiratory system, Female, Drug Monitoring, Cytokine Release Syndrome, business
Abstract: Summary Background Elevated proinflammatory cytokines are associated with greater COVID-19 severity. We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, in patients with severe (requiring supplemental oxygen by nasal cannula or face mask) or critical (requiring greater supplemental oxygen, mechanical ventilation, or extracorporeal support) COVID-19. Methods We did a 60-day, randomised, double-blind, placebo-controlled, multinational phase 3 trial at 45 hospitals in Argentina, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Russia, and Spain. We included adults (≥18 years) admitted to hospital with laboratory-confirmed SARS-CoV-2 infection and pneumonia, who required oxygen supplementation or intensive care. Patients were randomly assigned (2:2:1 with permuted blocks of five) to receive intravenous sarilumab 400 mg, sarilumab 200 mg, or placebo. Patients, care providers, outcome assessors, and investigators remained masked to assigned intervention throughout the course of the study. The primary endpoint was time to clinical improvement of two or more points (seven point scale ranging from 1 [death] to 7 [discharged from hospital]) in the modified intention-to-treat population. The key secondary endpoint was proportion of patients alive at day 29. Safety outcomes included adverse events and laboratory assessments. This study is registered with ClinicalTrials.gov, NCT04327388; EudraCT, 2020-001162-12; and WHO, U1111-1249-6021. Findings Between March 28 and July 3, 2020, of 431 patients who were screened, 420 patients were randomly assigned and 416 received placebo (n=84 [20%]), sarilumab 200 mg (n=159 [38%]), or sarilumab 400 mg (n=173 [42%]). At day 29, no significant differences were seen in median time to an improvement of two or more points between placebo (12·0 days [95% CI 9·0 to 15·0]) and sarilumab 200 mg (10·0 days [9·0 to 12·0]; hazard ratio [HR] 1·03 [95% CI 0·75 to 1·40]; log-rank p=0·96) or sarilumab 400 mg (10·0 days [9·0 to 13·0]; HR 1·14 [95% CI 0·84 to 1·54]; log-rank p=0·34), or in proportions of patients alive (77 [92%] of 84 patients in the placebo group; 143 [90%] of 159 patients in the sarilumab 200 mg group; difference −1·7 [−9·3 to 5·8]; p=0·63 vs placebo; and 159 [92%] of 173 patients in the sarilumab 400 mg group; difference 0·2 [−6·9 to 7·4]; p=0·85 vs placebo). At day 29, there were numerical, non-significant survival differences between sarilumab 400 mg (88%) and placebo (79%; difference +8·9% [95% CI −7·7 to 25·5]; p=0·25) for patients who had critical disease. No unexpected safety signals were seen. The rates of treatment-emergent adverse events were 65% (55 of 84) in the placebo group, 65% (103 of 159) in the sarilumab 200 mg group, and 70% (121 of 173) in the sarilumab 400 mg group, and of those leading to death 11% (nine of 84) were in the placebo group, 11% (17 of 159) were in the sarilumab 200 mg group, and 10% (18 of 173) were in the sarilumab 400 mg group. Interpretation This trial did not show efficacy of sarilumab in patients admitted to hospital with COVID-19 and receiving supplemental oxygen. Adequately powered trials of targeted immunomodulatory therapies assessing survival as a primary endpoint are suggested in patients with critical COVID-19. Funding Sanofi and Regeneron Pharmaceuticals.
Published: 2021

45. Definition, aims, and implementation of GA [sup] 2 LEN/HAEi Angioedema Centers of Reference and Excellence

Author: Kemal Özyurt, Teresa Caballero, Aharon Kessel, Andrew J. MacGinnitie, Solange Oliveira Rodrigues Valle, Anthony J. Castaldo, Markus Magerl, Regis A. Campos, Adam Reich, Heike Röckmann-Helmbach, R. Y. Meshkova, Mario Sánchez-Borges, Richard G. Gower, Anna Zalewska-Janowska, Daria Fomina, Célia Costa, Allen P. Kaplan, Marc A. Riedl, Naoko Inomata, Avner Reshef, Alejandro Malbrán, Aurélie Du-Thanh, N. Prior, Hilary Longhurst, Margarida Gonçalo, Kiran Godse, Rosana Câmara Agondi, Andreas Kleinheinz, Inmaculada Martinez-Saguer, Mona Al-Ahmad, Thilo Jakob, Luis Felipe Ensina, José Ignacio Larco Sousa, Anna Tagka, Chikako Nishigori, Nicola Wagner, Hye Ryun Kang, Michael Makris, Nicholas Brodszki, Ricardo Dario Zwiener, Jan Nicolay, Alicja Kasperska-Zając, Iris V Medina, Ignacio J. Ansotegui, Marcin Stobiecki, Alejandro Berardi, Danny M. Cohn, Claudio A S Parisi, Angèle Soria, Torsten Zuberbier, Dario O. Josviack, E Serra-Baldrich, Jonathan A. Bernstein, Anette Bygum, Isao Ohsawa, Henriette Farkas, Iman Nasr, Thomas Buttgereit, Jonathan Peter, Carsten Bindslev-Jensen, Paulo Ricardo Criado, Wolfgang Pfützner, Natalia Fili, Silvia Mariel Ferrucci, Petra Staubach, Peter Schmid-Grendelmeier, M. Gotua, Marcus Maurer, Jose Fabiani, Gordon Sussman, A. Marsland, Konrad Bork, Andrea Zanichelli, Simon Francis Thomsen, Isabelle Boccon-Gibod, Mauro Cancian, German D. Ramon, Zuotao Zhao, Nikolaos G. Papadopoulos, Martijn B. A. van Doorn, Andrea Bauer, Kanokvalai Kulthanan, Claudio Fantini, Henrik Balle Boysen, Lilian Varga, Dorota Krasowska, Ana Giménez-Arnau, Werner Aberer, Ivan Cherrez-Ojeda, Roberta F. Criado, Constance H. Katelaris, Martin Metz, Riccardo Asero, Mitja Košnik, Stephen Betschel, M Sendhil Kumaran, Sigurd Broesby-Olsen, Moshe Ben-Shoshan, Rand Arnaout, Regina Treudler, Laurence Bouillet, Natalia Ilina, Maryam Ali Al-Nesf, Emek Kocatürk, Emel Aygören-Pürsün, William R. Lumry, Guillermo Guidos-Fogelbach, Yuxiang Zhi, Mark Gompels, Andac Salman, Christina Weber-Chrysochoou, Michihiro Hide, Young Min Ye, Aslı Gelincik, William B Smith, Timothy J. Craig, Bruce Ritchie, Daniel O. Vázquez, Mojca Bizjak, Atsushi Fukunaga, Ragıp Ertaş, Urs C. Steiner, Faradiba Sarquis Serpa, Farrukh R. Sheikh, Michael Rudenko, Paula J. Busse, Luisa Karla de Paula Arruda, Liangchun Wang, Todor A. Popov, Anete Sevciovic Grumach, Joachim Dissemond, Dorottya Csuka, Ignasi Figueras-Nart, Aleena Banerji, Tıp Fakültesi, Kemal Özyurt / 0000-0002-6913-8310, Vascular Medicine, ACS - Atherosclerosis & ischemic syndromes, Dermatology, Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Maurer, Marcus, Werner, Aberer, Agondi, Rosana, Al-Ahmad, Mona, Al-Nesf, Maryam Ali, Ansotegui, Ignacio, Arnaout, Rand, Arruda, Luisa Karla, Asero, Riccardo, Aygoeren-Puersue, Emel, Banerji, Aleena, Bauer, Andrea, Ben-Shoshan, Moshe, Berardi, Alejandro, Bernstein, Jonathan A, Betschel, Stephen, Bindslev-Jensen, Carsten, Bizjak, Mojca, Boccon-Gibod, Isabelle, Bork, Konrad, Bouillet, Laurence, Boysen, Henrik Balle, Brodszki, Nicholas, Broesby-Olsen, Sigurd, Busse, Paula, Buttgereit, Thomas, Bygum, Anette, Caballero, Teresa, Campos, Regis A., Cancian, Mauro, Cherrez-Ojeda, Ivan, Cohn, Danny M., Costa, Celia, Craig, Timothy, Criado, Paulo Ricardo, Criado, Roberta F., Csuka, Dorottya, Dissemond, Joachim, Du-Thanh, Aurelie, Ensina, Luis Felipe, Ertaş, Ragıp, Fabiani, Jose E., Fantini, Claudio, Farkas, Henriette, Ferrucci, Silvia Mariel, Figueras-Nart, Ignasi, Fili, Natalia L., Fomina, Daria, Fukunaga, Atsushi, Gelincik, Aslı, Gimenez-Arnau, Ana, Godse, Kiran, Gompels, Mark, Goncalo, Margarida, Gotua, Maia, Gower, Richard, Grumach, Anete S, Guidos-Fogelbach, Guillermo, Hide, Michihiro, Ilina, Natalia, Inomata, Naoko, Jakob, Thilo, Josviack, Dario O., Kang, Hye-Ryun, Kaplan, Allen, Kasperska-Zajac, Alicja, Katelaris, Constance, Kessel, Aharon, Kleinheinz, Andreas, Kosnik, Mitja, Krasowska, Dorota, Kulthanan, Kanokvalai, Kumaran, M. Sendhil, Larco Sousa, Jose Ignacio, Longhurst, Hilary J., Lumry, William, MacGinnitie, Andrew, Magerl, Markus, Makris, Michael P., Malbran, Alejandro, Marsland, Alexander, Martinez-Saguer, Inmaculada, Medina, Iris V., Meshkova, Raisa, Metz, Martin, Nasr, Iman, Nicolay, Jan, Nishigori, Chikako V., Nishigori, Chikako, Ohsawa, Isao, Özyurt, Kemal, Papadopoulos, Nikolaos G., Parisi, Claudio A. S., Peter, Jonathan Grant, Pfuetzner, Wolfgang, Popov, Todor, Prior, Nieves, Ramon, German D., Reich, Adam, Reshef, Avner, Riedl, Marc A., Ritchie, Bruce, Rockmann-Helmbach, Heike, Rudenko, Michael, Salman, Andaç, Sanchez-Borges, Mario, Schmid-Grendelmeier, Peter, Serpa, Faradiba S., Serra-Baldrich, Esther, Sheikh, Farrukh R., Smith, William, Soria, Angele, Staubach, Petra, Steiner, Urs C., Stobiecki, Marcin, Sussman, Gordon, Tagka, Anna, Thomsen, Simon Francis, Treudler, Regina, Valle, Solange, van Doorn, Martijn, Varga, Lilian, Vazquez, Daniel O., Wagner, Nicola, Wang, Liangchun, Weber-Chrysochoou, Christina, Ye, Young-Min, Zalewska-Janowska, Anna, Zanichelli, Andrea, Zhao, Zuotao, Zhi, Yuxiang, Zuberbier, Torsten, Zwiener, Ricardo D., Castaldo, Anthony, and School of Medicine
Subjects: medicine.medical_specialty, Edema angioneuròtic, Urticaria, media_common.quotation_subject, Immunology, education, GA2LEN, Angioedema, Center, Excellence, Management, urticaria, centres of reference and excelence, immune system diseases, center, medicine, Immunology and Allergy, Center (algebra and category theory), Angioneurotic edema, skin and connective tissue diseases, media_common, udc:616.1, business.industry, angioedema, humanities, referenčni centri odličnosti, Medicine, Allergy, Family medicine, excellence, medicine.symptom, business, Global Allergy and Asthma European Network, Urticària, management
Abstract: This document summarizes the aims of GA2 LEN/HAEi Angioedema Centers of Reference and Excellence (ACAREs) and elaborates the requirements that ACAREs must fulfill to become certified. It also provides (see Appendix S1) background information on GA2LEN and HAEi, including HAEi member organizations and regional patient advocates, on why we need an Angioedema Center of Reference and Excellence (ACARE) program and network, and on the accreditation and certification process, governance and funding, and on the interaction with other GA2LEN networks of centers of reference and excellence. The protocols, aims, requirements, and provisions related to becoming a certified CARE are based on (a) the experience of the GA2LEN UCARE network and (b) input from angioedema patients, general practitioners, and angioedema specialists.
Published: 2020

46. Temporal clinical and laboratory response to interleukin-6 receptor blockade with Tocilizumab in 89 hospitalized patients with COVID-19 pneumonia

Author: Inna V. Samsonova, Alexander Karaulov, Daria Fomina, Michael M. Lederman, Anton A. Chernov, Zinaida Yu. Mutovina, Irina P. Beloglazova, Nataliya G. Poteshkina, M. A. Lysenko, and Tat'yana S. Kruglova
Subjects: Mechanical ventilation, medicine.medical_specialty, biology, business.industry, medicine.medical_treatment, C-reactive protein, medicine.disease, Systemic inflammation, Gastroenterology, chemistry.chemical_compound, Pneumonia, Tocilizumab, chemistry, Internal medicine, Interleukin-6 receptor, medicine, biology.protein, Lymphocytopenia, medicine.symptom, business, Cytokine storm
Abstract: BackgroundEmerging evidence links morbidity and mortality of pandemic COVID-19 pneumonia to an inflammatory cytokine storm.MethodsEighty nine patients with COVID-19 pneumonia and heightened systemic inflammation (elevated serum C reactive protein and interleukin-6 levels) were treated with Tocilizumab (TCZ), a human monoclonal IgG1 antibody to the interleukin-6 receptor.ResultsClinical and laboratory improvement was seen comparing baseline and 1-2 day post-infusion indices. Among 72 patients not receiving mechanical ventilation, NEWS2 scores fell from 5 to 2 (p < 0.001) C reactive protein levels fell from 95 to 14 mg/L (p < 0.001) and lymphocyte counts rose from 900 to 1000/uL (p = 0.036). Sixty three of 72 patients were discharged from hospital, one patient died, and 8 remained in hospital at time of writing. Among 17 patients receiving mechanical ventilation, despite a rapid decrease in CRP levels from 89 to 35 mg/L (p = 0.014) and early improvements in NEWS2 scores in 10 of 17, ten patients died and seven remain in hospital at time of writing. Overall, mortality was only seen in patients who had markedly elevated CRP levels (>30 mg/L) and low lymphocyte counts (< 1000/uL) before TCZ administration.ConclusionsInflammation and lymphocytopenia are linked to mortality in COVID-19. Inhibition of IL-6 activity by administration of Tocilizumab, an anti IL-6 receptor antibody is associated with rapid improvement in both CRP and lymphocyte counts and in clinical indices. Controlled clinical trials are needed to confirm the utility of IL-6 blockade in this setting. Additional interventions will be needed for patients requiring mechanical ventilation.
Published: 2020
Full Text: View/download PDF

47. Definition, aims, and implementation of GA

Author: Marcus, Maurer, Werner, Aberer, Rosana, Agondi, Mona, Al-Ahmad, Maryam Ali, Al-Nesf, Ignacio, Ansotegui, Rand, Arnaout, Luisa Karla, Arruda, Riccardo, Asero, Emel, Aygören-Pürsün, Aleena, Banerji, Andrea, Bauer, Moshe, Ben-Shoshan, Alejandro, Berardi, Jonathan A, Bernstein, Stephen, Betschel, Carsten, Bindslev-Jensen, Mojca, Bizjak, Isabelle, Boccon-Gibod, Konrad, Bork, Laurence, Bouillet, Henrik Balle, Boysen, Nicholas, Brodszki, Sigurd, Broesby-Olsen, Paula, Busse, Thomas, Buttgereit, Anette, Bygum, Teresa, Caballero, Régis A, Campos, Mauro, Cancian, Ivan, Cherrez-Ojeda, Danny M, Cohn, Célia, Costa, Timothy, Craig, Paulo Ricardo, Criado, Roberta F, Criado, Dorottya, Csuka, Joachim, Dissemond, Aurélie, Du-Thanh, Luis Felipe, Ensina, Ragıp, Ertaş, José E, Fabiani, Claudio, Fantini, Henriette, Farkas, Silvia Mariel, Ferrucci, Ignasi, Figueras-Nart, Natalia L, Fili, Daria, Fomina, Atsushi, Fukunaga, Asli, Gelincik, Ana, Giménez-Arnau, Kiran, Godse, Mark, Gompels, Margarida, Gonçalo, Maia, Gotua, Richard, Gower, Anete S, Grumach, Guillermo, Guidos-Fogelbach, Michihiro, Hide, Natalia, Ilina, Naoko, Inomata, Thilo, Jakob, Dario O, Josviack, Hye-Ryun, Kang, Allen, Kaplan, Alicja, Kasperska-Zając, Constance, Katelaris, Aharon, Kessel, Andreas, Kleinheinz, Emek, Kocatürk, Mitja, Košnik, Dorota, Krasowska, Kanokvalai, Kulthanan, M Sendhil, Kumaran, José Ignacio, Larco Sousa, Hilary J, Longhurst, William, Lumry, Andrew, MacGinnitie, Markus, Magerl, Michael P, Makris, Alejandro, Malbrán, Alexander, Marsland, Inmaculada, Martinez-Saguer, Iris V, Medina, Raisa, Meshkova, Martin, Metz, Iman, Nasr, Jan, Nicolay, Chikako, Nishigori, Isao, Ohsawa, Kemal, Özyurt, Nikolaos G, Papadopoulos, Claudio A S, Parisi, Jonathan Grant, Peter, Wolfgang, Pfützner, Todor, Popov, Nieves, Prior, German D, Ramon, Adam, Reich, Avner, Reshef, Marc A, Riedl, Bruce, Ritchie, Heike, Röckmann-Helmbach, Michael, Rudenko, Andaç, Salman, Mario, Sanchez-Borges, Peter, Schmid-Grendelmeier, Faradiba S, Serpa, Esther, Serra-Baldrich, Farrukh R, Sheikh, William, Smith, Angèle, Soria, Petra, Staubach, Urs C, Steiner, Marcin, Stobiecki, Gordon, Sussman, Anna, Tagka, Simon Francis, Thomsen, Regina, Treudler, Solange, Valle, Martijn, van Doorn, Lilian, Varga, Daniel O, Vázquez, Nicola, Wagner, Liangchun, Wang, Christina, Weber-Chrysochoou, Young-Min, Ye, Anna, Zalewska-Janowska, Andrea, Zanichelli, Zuotao, Zhao, Yuxiang, Zhi, Torsten, Zuberbier, Ricardo D, Zwiener, and Anthony, Castaldo
Subjects: Urticaria, Humans, Angioedema
Published: 2020

48. Common variable immune deficiency in adults: focus on pulmonary complications

Author: V V Parshin, Daria Fomina, D O Sinyavkin, and E.N. Bobrikova
Subjects: Adult, History, Pediatrics, medicine.medical_specialty, Adult patients, business.industry, Endocrinology, Diabetes and Metabolism, Common variable immunodeficiency, lcsh:R, pulmonary complications, lcsh:Medicine, General Medicine, Disease, intravenous immunoglobulins, medicine.disease, common variable immune deficiency, Common Variable Immunodeficiency, Intravenous Immunoglobulins, medicine, Humans, In patient, Family Practice, business, primary immunodeficiencies
Abstract: Common variable immune deficiency is the most common form of a group of primary immunodeficiencies in adult patients. Pulmonary complications occupy leading positions. It is the development of recurrent bronchopulmonary inflammatory diseases that is considered to be one of the main causes of death and disability in patients with this disease. By presenting two clinical cases with long diagnostic delays, the authors try to attract the attention of specialists of related professions, which will minimize the development of irreversible complications in the patients.Общая вариабельная иммунная недостаточность - наиболее частая форма первичных иммунодефицитов у взрослых больных. Лидирующие позиции занимают пульмонологический осложнения. Одной из основных причин смерти и инвалидизации больных считается именно развитие рецидивирующих бронхолегочных воспалительных заболеваний. Представляя два клинических случая с большим опозданием в установлении диагноза, мы стараемся привлечь внимание специалистов смежных специальностей, что позволит минимизировать развитие необратимых осложнений у пациентов с данным заболеванием.
Published: 2017

49. SARS-CoV-2 infection and COVID-19 in asthmatics: a complex relationship

Author: Min Xie, Daria Fomina, Sharon Chinthrajah, Alexander Karaulov, Harald Renz, Kari C. Nadeau, Antonina Karsonova, and Chrysanthi Skevaki
Subjects: 0301 basic medicine, Risk, History, medicine.medical_specialty, Endotype, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Pulmonary disease, macromolecular substances, Severity of Illness Index, Education, 03 medical and health sciences, Pulmonary Disease, Chronic Obstructive, 0302 clinical medicine, Th2 Cells, Internal medicine, Severity of illness, Epidemiology, Eosinophilia, medicine, Humans, RNA, Messenger, Asthma, COPD, Interleukin-13, business.industry, SARS-CoV-2, Comment, COVID-19, Th1 Cells, medicine.disease, Computer Science Applications, respiratory tract diseases, 030104 developmental biology, Phenotype, Viral infection, Th17 Cells, Angiotensin-Converting Enzyme 2, Interleukin-4, Interleukin-5, business, 030215 immunology, Receptors, Coronavirus
Abstract: Risk of severe coronavirus disease 2019 (COVID-19) after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is increased in patients with certain comorbidities, including chronic obstructive pulmonary disease (COPD). By contrast, epidemiological data from many (but not all) countries indicate a low prevalence of asthma among patients with severe COVID-19. This reduced risk of severe COVID-19 may apply specifically to patients with the type 2 asthma endotype, which is most common in childhood asthma., Somewhat surprisingly, individuals with asthma do not seem to have a greater risk of developing severe COVID-19. Here, the authors offer mechanistic insights to explain the epidemiological data.
Published: 2021

50. The effectiveness of different treatment regimens in patients with Graves' ophthalmopathy

Author: Daria, Fomina, primary
Published: 2019
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Database

Publisher

57 results on '"Daria Fomina"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources